10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________to __________

Commission file number: 000-26495

CYREN LTD.

(Exact name of Registrant as specified in its charter)

Israel	Not applicable
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

10 Ha-Menofim St., 5th Floor Herzliya, Israel	4672561
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code 011–972–9–863–6888

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which  Registered
Ordinary Shares, par value ILS 3.00 per share	CYRN	Nasdaq Capital Market

Indicate the number of shares outstanding of each issuer’s classes of common shares, as of the latest practicable date: 7,999,808 ordinary shares as of October 31, 2022.

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-Accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒

CYREN LTD.

QUARTERLY REPORT ON FORM 10-Q

Table of Contents

		Page
PART I – FINANCIAL INFORMATION
Item 1.	Financial Statements
	Consolidated Balance Sheets as of September 30, 2022 (unaudited) and December 31, 2021	1
	Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2022, and 2021	3
	Consolidated Statements of Comprehensive Loss (unaudited) for the three and nine months ended September 30, 2022, and 2021	4
	Consolidated Statement of Changes in Shareholders’ Equity (unaudited) for the three and nine months ended September 30, 2022, and 2021	5
	Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2022, and 2021	6
	Notes to Consolidated Financial Statements (unaudited)	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	22
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	33
Item 4.	Controls and Procedures	35
PART II – OTHER INFORMATION		36
Item 1A	Risk Factors	36
Item 6.	Exhibits	36
SIGNATURES		37

i

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

CYREN LTD.

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2022		December 31, 2021
(USD in thousands, except share and per share amounts)	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	13,520	$	4,288
Trade receivables (net of allowances for credit losses of $97 and $118, respectively)	1,234		352
Deferred commissions	706		482
Prepaid expenses and other receivables	2,451		1,120
Current assets held for sale (Note 3)	—		1,082
Total current assets	17,911		7,324
LONG-TERM ASSETS:
Long-term deferred commissions	797		521
Long-term lease deposits and prepaid expenses	630		686
Operating lease right-of-use assets	5,265		6,207
Severance pay fund	740		921
Property and equipment, net	1,126		1,980
Intangible assets, net	1,750		3,499
Goodwill	6,518		11,598
Long-term assets held for sale (Note 3)	—		13,392
Total long-term assets	16,826		38,804
Total assets	$	34,737	$	46,128

-1-

	September 30, 2022		December 31, 2021
(USD in thousands, except share and per share amounts)	(Unaudited)
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Trade payables	$	1,228	$	1,059
Employees and payroll accruals	3,230		4,196
Accrued expenses and other liabilities ($0 and $4 attributable to related parties, respectively)	1,342		937
Operating lease liabilities	1,083		1,330
Deferred revenues	6,581		3,004
Current liabilities held for sale (Note 3)	439		2,180
Total current liabilities	13,903		12,706
LONG-TERM LIABILITIES:
Deferred revenues	2,590		72
Convertible Debentures ($242 and $238 attributable to related parties, respectively)	8,717		8,578
Long-term operating lease liabilities	4,293		5,749
Deferred tax liability, net	157		167
Accrued severance pay	833		983
Other liabilities	447		517
Long-term liabilities held for sale (Note 3)	—		3,528
Total long-term liabilities	17,037		19,594
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:
Ordinary shares nominal value ILS 3.00 par value; Authorized: 80,000,000 shares as of September 30, 2022 (Unaudited) and December 31, 2021; Issued and Outstanding: 7,999,808 and 4,532,943 shares as of September 30, 2022 (Unaudited) and December 31, 2021, respectively	6,890		3,759
Additional paid-in capital	293,555		283,577
Accumulated other comprehensive loss	—		(1,877)
Accumulated deficit	(296,648)		(271,631)
Total shareholders’ equity	3,797		13,828
Total liabilities and shareholders’ equity	$	34,737	$	46,128

The accompanying notes are an integral part of the interim consolidated financial statements.

-2-

CYREN LTD.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited and USD in thousands, except share and per share amounts)	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Revenues	$	5,834	$	5,616	$	17,302	$	18,166
Cost of revenues	3,015		3,311		9,677		9,941
Gross profit	2,819		2,305		7,625		8,225
Operating expenses:
Research and development, net	3,449		3,516		11,174		10,606
Sales and marketing	2,705		2,447		7,677		7,097
General and administrative	2,178		2,162		6,972		6,262
Total operating expenses	8,332		8,125		25,823		23,965
Operating loss	(5,513)		(5,820)		(18,198)		(15,740)
Other (expense) income, net	(4)		4		(6)		(13)
Financial income (expenses), net ($5 and $148 interest expense attributable to related parties for the three months ended September 30, 2022, and 2021, respectively)	(7)		(282)		104		(705)
Loss from continuing operations before taxes on income	(5,524)		(6,098)		(18,100)		(16,458)
Tax benefit (expense)	1		(20)		12		43
Net loss from continuing operations	(5,523)		(6,118)		(18,088)		(16,415)
Discontinued operations (Note 3):
Income (loss) from operations of discontinued operations	(575)		331		(6,929)		843
Net loss	$	(6,098)	$	(5,787)	$	(25,017)	$	(15,572)
Basic net income (loss) per share:
Continuing operations	$	(0.71)	$	(1.57)	$	(2.64)	$	(4.44)
Discontinued operations	$	(0.07)	$	0.08	$	(1.01)	$	0.23
Basic net loss per share	$	(0.78)	$	(1.48)	$	(3.65)	$	(4.21)
Diluted net income (loss) per share:
Continuing operations	$	(0.71)	$	(1.57)	$	(2.64)	$	(4.44)
Discontinued operations	$	(0.07)	$	0.07	$	(1.01)	$	0.19
Diluted net loss per share	$	(0.78)	$	(1.50)	$	(3.65)	$	(4.25)
Weighted-average number of shares used in computing basic net income (loss) per share and diluted loss per share for continuing operations	7,822,424		3,899,502		6,858,937		3,700,789
Weighted-average numbers of shares used in computing basic net income (loss) per share for discontinued operations	7,822,424		3,899,502		6,858,937		3,700,789
Weighted-average numbers of shares used in computing diluted net income (loss) per share for discontinued operations	7,822,424		4,671,832		6,858,937		4,457,946

The accompanying notes are an integral part of the interim consolidated financial statements.

-3-

CYREN LTD.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands, except share and per share amounts)	2022		2021		2022		2021
Net loss	$	(6,098)	$	(5,787)	$	(25,017)	$	(15,572)
Other comprehensive loss:
Foreign currency translation adjustments	(203)		(351)		(1,225)		(838)
Comprehensive loss	$	(6,301)	$	(6,138)	$	(26,242)	$	(16,410)

The accompanying notes are an integral part of the interim consolidated financial statements.

-4-

CYREN LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(USD in thousands, except share and per share amounts)	Number of out standing ordinary shares	Share capital		Additional paid-in capital		Accumulated other compre hensive loss1		Accumulated deficit		Total shareholders’ equity
Balance as of December 31, 2020	3,063,596	$	2,392	$	258,962	$	(725)	$	(248,592)	$	12,037
Share issuance for financing, net of costs2	600,000	556		12,032		—		—		12,588
Restricted share units vested	32,100	30		(30)		—		—		—
Payment of interest in shares	14,572	13		246		—		—		259
Share-based compensation related to employees, directors and consultants	—	—		457		—		—		457
Issuance of shares upon early conversion of a Convertible Debentures	60,074	55		804		—		—		859
Other comprehensive loss	—	—		—		(659)		—		(659)
Net loss	—	—		—		—		(4,197)		(4,197)
Balance as of March 31, 2021 (Unaudited)	3,770,342	$	3,046	$	272,471	$	(1,384)	$	(252,789)	$	21,344
Payment of interest in shares	11,670	10		132		—		—		142
Share-based compensation related to employees, directors and consultants	—	—		548		—		—		548
Other comprehensive income	—	—		—		172		—		172
Net loss	—	—		—		—		(5,588)		(5,588)
Balance as of June 30, 2021 (Unaudited)	3,782,012	$	3,056	$	273,151	$	(1,212)	$	(258,377)	$	16,618
Issuance of shares and warrants, net of costs3	707,639	662		8,614		—		—		9,276
Restricted share units vested	11,813	11		(11)		—		—		—
Payment of interest in shares	16,726	16		243		—		—		259
Share-based compensation related to employees, directors and consultants	—	—		752		—		—		752
Other comprehensive loss	—	—		—		(351)		—		(351)
Net loss	—	—		—		—		(5,787)		(5,787)
Balance as of September 30, 2021 (Unaudited)	4,518,190	$	3,745	$	282,749	$	(1,563)	$	(264,164)	$	20,767

(USD in thousands, except share and per share amounts)	Number of out standing ordinary shares	Share capital		Additional paid-in capital		Accumulated other compre hensive loss1		Accumulated deficit		Total shareholders’ equity
Balance as of December 31, 2021	4,532,943	$	3,759	$	283,577	$	(1,877)	$	(271,631)	$	13,828
Issuance of shares and warrants, net of costs3	760,757	709		10,233		—		—		10,942
Restricted share units vested	70,322	9		(9)		—		—		—
Exercise of pre-funded warrants	365,059	345		(345)		—		—		—
Issuance of whole shares in lieu of fractional shares due to reverse stock split	15,589	—		—		—		—		—
Payment of interest in shares	31,667	29		230		—		—		259
Share-based compensation related to employees, directors and consultants	—	—		630		—		—		630
Other comprehensive loss	—	—		—		(251)		—		(251)
Net loss	—	—		—				(6,483)		(6,483)
Balance as of March 31, 2022 (Unaudited)	5,776,337	$	4,851	$	294,316	$	(2,128)	$	(278,114)	$	18,925
Restricted share units vested	7,998	—		—		—		—		—
Exercise of pre-funded warrants	2,003,259	1,873		(1,871)		—		—		2
Share-based compensation related to employees, directors and consultants	—	—		488		—		—		488
Other comprehensive loss	—	—		—		(771)		—		(771)
Net loss	—	—		—		—		(12,436)		(12,436)
Balance as of June 30, 2022 (Unaudited)	7,787,594	$	6,724	$	292,933	$	(2,899)	$	(290,550)	$	6,208
Restricted share units vested	21,942	—		—		—		—		—
Payment of interest in shares	190,272	166		93		—		—		259
Share-based compensation related to employees, directors and consultants	—	—		529		—		—		529
Realized foreign currency translation	—					3,102				3,102
Other comprehensive loss	—	—		—		(203)		—		(203)
Net loss	—	—		—		—		(6,098)		(6,098)
Balance as of September 30, 2022 (Unaudited)	7,999,808	$	6,890	$	293,555	$	—	$	(296,648)	$	3,797
1 Relates to foreign currency translation adjustments.
2 Net of issuance costs of $1,212
3 Net of issuance costs of $1,057

The accompanying notes are an integral part of the interim consolidated financial statements.

-5-

CYREN LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Nine Months Ended September 30,
(USD in thousands, except share and per share amounts)	2022		2021
Cash flows from operating activities:
Net loss	$	(25,017)	$	(15,572)
Less: Income (loss) from discontinued operations	(6,929)		843
Loss from continuing operations	(18,088)		(16,415)
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities from continuing operations:
(Gain) loss on disposal of property and equipment	(1)		17
Loss on termination of operating leases	13		—
Depreciation	1,042		1,532
Share-based compensation	1,647		1,705
Amortization of intangible assets	1,749		1,785
Amortization of deferred commissions	738		644
Operating lease right-of-use-asset	929		1,032
Interest on convertible notes	—		430
Interest and amortization of debt issuance costs on convertible debentures	520		523
Deferred taxes, net	(10)		(62)
Changes in assets and liabilities:
Trade receivables	(882)		(2,627)
Prepaid expenses and other receivables	(1,331)		(578)
Deferred commissions	(1,238)		(637)
Long-term lease deposits and prepaid expenses	19		(18)
Trade payables	597		(1,622)
Employees and payroll accruals, accrued expenses and other liabilities	(424)		2,012
Deferred revenues	6,095		137
Accrued severance pay, net	31		(48)
Operating lease liabilities	(1,703)		(1,196)
Other long-term liabilities	(70)		(390)
Net cash used in operating activities from continuing operations	(10,367)		(13,776)
Net cash provided by operating activities from discontinued operations	1,395		1,314
Net cash used in operating activities	(8,972)		(12,462)
Cash flows from investing activities:
Proceeds from sale of a business	8,076		—
Proceeds from sale of property and equipment	1		6
Capitalization of technology	—		(262)
Purchase of property and equipment	(177)		(466)
Net cash provided by (used in) investing activities from continuing operations	7,900		(722)
Net cash used in investing activities from discontinued operations	(709)		—
Net cash used in investing activities	7,191		(722)

The accompanying notes are an integral part of the interim consolidated financial statements.

-6-

	Nine Months Ended September 30,
(Unaudited and USD in thousands)	2022		2021
Cash flows from financing activities:
Proceeds from issuance of ordinary shares and warrants, net of issuance costs	10,942		—
Proceeds from stock issuance, net of costs	—		21,864
Proceeds from pre-funded warrants exercised	2		—
Net cash provided by financing activities	10,944		21,864
Effect of exchange rate changes on cash, cash equivalents and restricted cash	—		(36)
Increase in cash, cash equivalents and restricted cash	9,163		8,644
Cash, cash equivalents and restricted cash at the beginning of the period	4,951		9,914
Cash, cash equivalents and restricted cash at the end of the period	$	14,114	$	18,558
Supplemental disclosure of non-cash transactions:
Purchase of property and equipment by credit	$	(11)	$	(25)
Operating lease right-of-use asset exchanged for lease obligations	$	88	$	—
Issuance of shares on early conversion of Convertible Debentures	$	—	$	859
Issuance of shares for payment of interest on Convertible Notes	$	518	$	143
Reconciliation of cash, cash equivalents and restricted cash as shown in the condensed consolidated statements of cash flow:
Cash and cash equivalents	$	13,520	$	16,304
Restricted cash included in long-term restricted lease deposits	594		501
Cash, cash equivalents and restricted cash included in assets held for sale			1,753
Total cash, cash equivalents and restricted cash	$	14,114	$	18,558

The accompanying notes are an integral part of the interim consolidated financial statements.

-7-

CYREN LTD.

UNAUDITED NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - ORGANIZATION

Cyren Ltd. (henceforth “Cyren”) was incorporated under the laws of the State of Israel on February 10, 1991, and its legal form is a company limited by shares. Cyren listed its shares to the public on July 15, 1999, under the name Commtouch Software Ltd. and changed its legal name to Cyren Ltd. in January 2014. Cyren and its subsidiaries, unless otherwise indicated, are referred to in these condensed consolidated financial statements as the “Company.”

The Company is engaged in developing and marketing cyber security solutions to identify and protect threats in email and electronic files and from the Internet. The Company sells its cloud-based solutions worldwide, in both embedded and Software-as-a-Service (SaaS) models, to original equipment manufacturers (“OEM”), service providers and enterprises. The Company operates in one reportable segment, which constitutes its reporting unit.

Over the past several years, the Company has devoted substantially most of its effort to research and product development and increasing revenues through additional investments in sales & marketing.

The Company has incurred losses since inception and expects to continue to incur losses for the foreseeable future. The Company's accumulated deficit as of September 30, 2022, was $296.6 million and negative cash flows from operating activities during the nine month period ending September 30, 2022, was $9.0 million. At September 30, 2022, the Company’s cash and cash equivalents position was not sufficient to fund the Company’s planned operations for at least a year beyond the filing date of the condensed consolidated financial statements. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due.

The Company intends to finance operating costs over the next twelve months through a combination of utilizing existing cash on hand, reducing operating spend, potentially divesting assets, and future issuances of equity and/or debt securities.

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business.

The condensed consolidated financial statements for the three and nine months ended September 30, 2022, do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

On February 10, 2022, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company issued and sold, in a private placement, an aggregate of 760,757 ordinary shares, pre-funded warrants to purchase up to 2,368,318 ordinary shares and ordinary warrants to purchase up to 3,129,075 ordinary shares for aggregate gross proceeds of approximately $12 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The purchase price of each ordinary share and associated ordinary warrant was $3.835 and the purchase price of each pre-funded warrant and associated ordinary warrant was $3.834. The ordinary warrants have an exercise price of $3.71, became exercisable upon issuance and expire on August 16, 2027. The pre-funded warrants have an exercise price of $0.001 and became exercisable upon issuance until exercised in full. The closing of the private placement occurred on February 14, 2022. The proceeds of the offering have been and continue to be used for working capital and general corporate purposes.

On June 1, 2022, the Company entered into a definitive Sale and Purchase Agreement (the “SPA”) with Content Services Group GmbH to sell all the equity interests in the Company’s legacy secure email gateway business and wholly owned subsidiary, Cyren GmbH (the “Cyren GmbH Transaction”). Pursuant to the SPA, the purchase price was €10.0 million in cash, subject to customary post-closing adjustments. Refer to Note 3 - Assets Held for Sale and Discontinued Operations for additional information.

On August 1, 2022, the Company completed the Cyren GmbH Transaction and received the initial €9.4 million payment (equivalent to $9.6 million as of the closing date). Under the terms of the SPA, a holdback in the amount of €0.7 million (the "Holdback Amount") is currently held in an escrow to satisfy certain claims. The Holdback Amount,

-8-

CYREN LTD.

UNAUDITED NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

less deductions for claims against the Company, if any, will be released to the Company no later than twelve months after the closing date.

Subsequent to the closing date, the Company paid approximately $1.4 million in expenses associated with the Cyren GmbH Transaction. Furthermore, the Company estimates that the final purchase price will be reduced by $0.4 million based on working capital and other adjustments and has accrued a current liability as of September 30, 2022. Beyond that, the Company is using the proceeds from the sale for working capital and general corporate purposes.

On May 5, 2022, the Company formed a new German subsidiary, Cyren Germany GmbH, which has assumed a portion of Cyren GmbH's former operations as of the closing of the Cyren GmbH Transaction, including a datacenter and shared services center for the Company. Cyren Germany GmbH began operations in August 2022.

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

Interim Financial Statements

The accompanying consolidated balance sheet as of September 30, 2022, the consolidated statements of operations, the consolidated statements of comprehensive loss for the three and nine months ended September 30, 2022, and 2021, and the consolidated statements of cash flows for the nine months ended September 30, 2022, and 2021, as well as the statement of changes in shareholders’ equity for the three and nine months ended September 30, 2022, are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the "SEC") regarding interim financial reporting. In management’s opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company’s financial position as of September 30, 2022, as well as its results of operations for the three and nine months ended September 30, 2022, and 2021 and cash flows for the nine months ended September 30, 2022, and 2021. The results of operations for the three and nine months ended September 30, 2022, are not necessarily indicative of the results to be expected for the year ending December 31, 2022, or for other interim periods or for future years.

Significant Accounting Policies

The accompanying unaudited interim consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Annual Report”) filed with the SEC on March 24, 2022.

Other than the change described below in Recently Issued and Adopted Pronouncements, there have been no changes to the significant accounting policies described in the 2021 Annual Report that have had a material impact on the unaudited interim consolidated financial statements and related notes.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the Company's consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities including goodwill impairment and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

-9-

CYREN LTD.

UNAUDITED NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

Discontinued Operations

A component of an entity that is disposed of by sale or abandonment is reported as discontinued operations if the transaction represents a strategic shift that will have a major effect on an entity's operations and financial results. Assets and liabilities of the discontinued operations are aggregated and reported separately in the Condensed Consolidated Balance Sheet, including the comparative prior year period. The results of discontinued operations are aggregated and presented separately in the Condensed Consolidated Statement of Operations. The disposed component cash flows are reflected as cash flows from discontinued operations within the Company’s Condensed Consolidated Statements of Cash Flows for each period presented. The Cyren GmbH Transaction was accounted for as discontinued operations and is presented in the Condensed Consolidated Balance Sheets as assets and liabilities held for sale. The results of discontinued operations are presented separately in the Condensed Consolidated Statements of Operation as discontinued operations.

Goodwill

Goodwill represents the excess of the purchase price over the estimated fair value of net assets of a business acquired in a business combination. Under ASC Topic 350, Intangibles - Goodwill and Other ("ASC 350"), goodwill is not amortized, but rather is subject to impairment test at least annually. The Company performs an annual impairment test as of December 31 of each year, or more frequently if events or changes in circumstances indicate the carrying value may not be recoverable. Goodwill is tested for impairment at the reporting unit level by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the reporting unit does not pass the qualitative assessment, the Company carries out a quantitative test for impairment of goodwill by comparing the fair value of the reporting unit with the carrying amount of the reporting unit that includes goodwill. The Company may bypass the qualitative assessment and proceed directly to performing the quantitative goodwill impairment test.

The Company operates in one operating segment, and this segment comprises its only reporting unit.

For the year ended December 31, 2021, no impairment losses were identified. For the three and nine months ended September 30, 2022, refer to Note 3 - Assets Held for Sale and Discontinued Operations.

Recently Issued and Adopted Pronouncements

In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-06, ASC Subtopic 470-20 Debt—Debt with Conversion and Other Options and ASC 815-40 Hedging—Contracts in Entity’s Own Equity. The standard reduced the number of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company early adopted this new guidance January 1, 2022. The adoption of ASU 2020-06 did not have a material impact on the consolidated financial statements.

-10-

CYREN LTD.

UNAUDITED NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 3 - ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS

As a result of the Cyren GmbH Transaction, the Company recorded certain assets as held for sale in its Condensed Consolidated Balance Sheet as of December 31, 2021. Additionally, the Company has recorded a loss on classification as held for sale in its Consolidated Condensed Statements of Operations for the three and nine months ended September 30, 2022, and 2021. Furthermore, the Company estimates that the final purchase price will be reduced by $0.4 million based on working capital and other adjustments and has accrued a current liability as of September 30, 2022. Refer to Note 1 - Organization for additional information.

The following assets and liabilities allocated to the discontinued operation are reflected as assets and liabilities of discontinued operations in the Company’s Consolidated Balance Sheet for the period presented. The major classes of assets and liabilities included as part of discontinued operations as of December 31, 2021, are presented in the following table:

(USD in thousands, except share and per share amounts)	December 31, 2021
Assets held for sale
Cash and cash equivalents	$	14
Trade receivables (net of allowances for credit losses of $19 and $40, respectively)	447
Deferred commissions	500
Prepaid expenses and other receivables	121
Long-term deferred commissions	412
Long-term lease deposits and prepaid expenses	123
Operating lease right-of-use assets	3,073
Property and equipment, net	203
Intangible assets, net	805
Goodwill	8,776
Total assets held for sale	$	14,474
Liabilities held for sale
Trade payables	$	16
Employees and payroll accruals	218
Accrued expenses and other liabilities	18
Operating lease liabilities	288
Deferred revenues - current	1,640
Deferred revenues - long-term	413
Long-term operating lease liabilities	2,875
Deferred tax liability, net	240
Total liabilities held for sale	$	5,708

-11-

CYREN LTD.

UNAUDITED NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

The following details the Company's results of discontinued operations.

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands, except share and per share amounts)	2022		2021		2022		2021
Revenues	$	441	$	1,845	$	3,397	$	5,661
Cost of revenues	88		421		870		1,391
Gross profit	353		1,424		2,527		4,270
Operating expenses:
Research and development, net	139		584		1,140		1,854
Sales and marketing	19		338		484		1,057
General and administrative	36		174		371		539
Total operating expenses	194		1,096		1,995		3,450
Operating gain	159		328		532		820
Other income (expense), net	(34)		1		(33)		1
Financial expenses, net	(505)		(38)		(517)		(116)
Income (loss) from discontinued operations before taxes on income	(380)		291		(18)		705
Loss on sale	(195)		—		(6,985)		—
Total income (loss) from discontinued operations before taxes on income	(575)		291		(7,003)		705
Tax benefit	—		40		74		138
Net income (loss) from discontinued operations	(575)		331		(6,929)		843

The following table presents the loss associated with the sale, presented in the results of discontinued operations:

Gross purchase price	$	10,264
Transaction costs	(1,422)
Provision	(439)
Net assets sold	(12,286)
Realized foreign currency translation adjustments	(3,102)
Total net loss on divestiture	$	(6,985)

-12-

CYREN LTD.

UNAUDITED NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 - LEASES

The Company accounts for leases according to ASC 842, Leases. The Company determines if an arrangement is a lease and the classification of that lease at inception. Right-of-use (“ROU”) assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. For leases with terms greater than 12 months, the Company records the ROU asset and liability at commencement date based on the present value of lease payments according to their term.

The Company uses incremental borrowing rates based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expenses are recognized on a straight-line basis over the lease term.

In addition, the carrying amount of the ROU and lease liabilities are remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset.

The Company elected the practical expedient for lease agreements with a term of twelve months or less and does not recognize ROU assets and lease liabilities in respect of those agreements. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.

The Company has various operating leases for office space and vehicles that expire through 2028. Below is a summary of the Company’s operating ROU assets and operating lease liabilities as of September 30, 2022:

	(Unaudited and USD in thousands)
Operating lease right-of-use assets	$	5,265
Operating lease liabilities, current	1,083
Operating lease liabilities long-term	4,293
Total operating lease liabilities	$	5,376

Minimum lease payments for the Company’s ROU assets over the remaining lease periods as of September 30, 2022, adjusted for discontinued operations, are as follows:

Year ended September 30,	(Unaudited and USD in thousands)
2022	$	314
2023	1,280
2024	1,127
2025	1,058
2026	1,001
Thereafter	1,141
Total undiscounted lease payments	$	5,921
Less: Interest	545
Present value of lease liabilities	$	5,376

Premises rent expense from continued operations was $430 and $574 for the three months ended September 30, 2022, and 2021, respectively, and $1,469 and $1,780 for the nine months ended September 30, 2022, and 2021, respectively.

-13-

CYREN LTD.

UNAUDITED NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

During the quarter ended September 30, 2022, the Company subleased one real estate property as lessor, however this lease terminated in July 2022. Sublease receipts were $10 and $167 for the three months ended September 30, 2022 and 2021, respectively, and $202 and $496 for the nine months ended September 30, 2022 and 2021, respectively.

The weighted-average remaining lease terms and discount rates for all operating leases were as follows as of September 30, 2022:

Weighted-average remaining lease term (years)	5.1
Weighted-average discount rate	4.10	%

NOTE 5 - COMMITMENTS AND CONTINGENCIES

The Company, which was incorporated in Israel, has partially financed its research and development expenditures under programs sponsored by the Israel Innovation Authority (“IIA”) for the support of certain research and development activities conducted in Israel.

Since the Company's inception through 2018, the Company received $6.4 million of participation payments from the IIA in connection with specific research and development. Of this amount, $2.6 million was subject to repayment to the IIA through royalties related to product sales as of September 30, 2022, and December 31, 2021. In return for the IIA’s participation in this program, the Company is committed to pay royalties at a rate of 3% of the program’s developed product sales, up to 100% of the amount of grants received plus interest at the annual LIBOR rate. For the three months ended September 30, 2022, and 2021, the Company recorded zero and $31 thousand, respectively, as cost of revenues with respect to royalties due to the IIA. For the nine months ended September 30, 2022, and 2021, the Company recorded zero and $90 thousand, respectively, as cost of revenues with respect to royalties due to the IIA.

The Company is not currently involved in any legal proceedings or claims.

NOTE 6 - SHAREHOLDERS’ EQUITY

General

Ordinary shares confer upon their holders the right to receive notice to participate and vote in general shareholder meetings of the Company and to receive dividends, if declared.

On February 7, 2022, the Company held a Special Meeting of Shareholders (the “Special Meeting”). At the Special Meeting, the Company’s shareholders approved (i) an amendment to the Company’s Amended and Restated Articles of Association (the “Articles of Association”) to effect a reverse share split of the Company’s ordinary shares (the “Reverse Share Split”) at a ratio of not less than one-for-four and not more than one-for-twenty, with such ratio and the implementation and timing of the Reverse Share Split to be determined by the Company’s board of directors in its sole discretion within thirty days of the Special Meeting and (ii) an increase in the authorized share capital by up to NIS 216.0 million to 240.0 million and an amendment to the Company’s Articles of Association accordingly.

Following the Special Meeting, on February 7, 2022, the board of directors of the Company approved a one-for-twenty Reverse Share Split and an increase in the Company’s authorized share capital by NIS 216.0 million, and the Articles of Association of the Company were amended accordingly. The Reverse Share Split became effective on February 9, 2022. Additionally, effective at the same time, the total number of ordinary shares the Company is authorized to issue after the effect of the Reverse Share Split is 80 million, the par value per ordinary share is NIS 3.00 and the authorized share capital of the Company is NIS 240.0 million.

Upon the effectiveness of the Reverse Share Split, every twenty ordinary shares were automatically combined and converted into one ordinary share. Appropriate adjustments were also made to all outstanding derivative securities of the Company, including all outstanding equity awards and warrants.

No fractional shares were issued in connection with the Reverse Share Split. Instead, all fractional shares (including shares underlying outstanding equity awards and warrants) were rounded up to the nearest whole ordinary share.

All the ordinary shares and per share data have been retroactively adjusted for the impact of the Reverse Share Split.

-14-

CYREN LTD.

UNAUDITED NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

Issuance of Convertible Notes

On December 5, 2018, the Company issued $10.0 million aggregate principal amount of convertible notes in a private offering. The notes were unsecured, unsubordinated obligations of Cyren and carried a 5.75% interest rate, payable semi-annually in (i) 50% cash and (ii) 50% cash or ordinary shares at Cyren’s election. The notes had a 3-year term and matured in December 2021. The notes were issued with a conversion price of $3.90 per share which was subject to adjustment using a weighted-average ratchet mechanism based on the size and price of future equity offerings and the total shares outstanding. On November 7, 2019, Cyren announced the closing of a rights offering that raised gross proceeds of $8.0 million. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.73. On February 16, 2021, Cyren announced securities purchase agreements with several institutional investors for the purchase and sale, in a registered direct offering, of 12.0 million of the Company’s ordinary shares at a purchase price of $1.15 per share for net proceeds of $12.6 million. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.38. On September 17, 2021, the Company issued to several institutional investors in a private placement 14,152,779 ordinary shares at a purchase price of $0.72 per share and warrants to purchase up to 14,152,779 ordinary shares at an exercise price of $0.60 per share. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.02 per share. In addition, the notes were subject to immediate conversion upon any change in control in the Company (or subject to repayment if the price in the change in control transaction is less than the conversion price).

The principal balance of $10.0 million on the convertible notes was repaid upon maturity on December 5, 2021. No further obligations remain with respect to the convertible notes.

The Company incurred no interest expense for the three and nine months ended September 30, 2022. The Company incurred interest expense of $0.1 million and $0.4 million for the three and nine months ended September 30, 2021.

Issuance of Convertible Debentures

In March 2020, the Company entered into purchase agreements with a select group of accredited investors for the purchase of $10.3 million aggregate principal amount of Convertible Debentures in a private placement. Upon the closing, the Company received approximately $9.4 million (net of $0.8 million in issuance expenses).

The debentures are unsecured, subordinated obligations of Cyren and carry a 5.75% interest rate per annum, payable semi-annually in cash or ordinary shares at Cyren’s election. The debentures have a four-year term and mature in March 2024, unless converted in accordance with their terms prior to maturity. The debentures have a conversion price of $15.00 per share and are convertible into 67 ordinary shares per $1.0 million principal amount of debentures. The conversion price is subject to adjustment based on the price and timing of future equity offerings and other customary adjustments. Upon the satisfaction of price and other conditions, Cyren has the right to force the conversion of the debentures.

In March 2021, the Company paid semi-annual interest payments totaling $0.3 million through the issuance of 14,572 shares of common stock. In September 2021, the Company paid semi-annual interest payments totaling $0.3 million through the issuance of 16,726 shares. In March 2022, the Company paid semi-annual interest payments totaling $0.3 million through the issuance of 31,667 shares of common stock. In September 2022, the Company paid semi-annual interest payments totaling $0.3 million through the issuance of 190,272 shares of common stock.

For the quarter ended March 31, 2021, two debenture holders converted a combined $1 million of principal plus interest of their debentures, which was a portion of their holdings. The principal and interest were paid through the issuance of 60,074 shares. There were no conversions for the quarter ended September 30, 2022.

The Company incurred interest expense of $176 thousand and $520 thousand for the three and nine months ended September 30, 2022, of which $48 thousand and $139 thousand was related to the amortization of debt issuance costs, respectively. The Company incurred interest expense of $180 thousand and $523 thousand for the three and nine months ended September 30, 2021, of which $44 thousand and $134 thousand was related to the amortization of debt issuance costs, respectively.

The Company had no accrued interest as of September 30, 2022, and $137 thousand as of December 31, 2021, respectively.

The principal balance of the Convertible Debentures as of September 30, 2022, was $8.7 million.

-15-

CYREN LTD.

UNAUDITED NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

Amended and Restated 2016 Equity Incentive Plan

On December 22, 2016, the Company’s shareholders approved the 2016 Equity Incentive Plan (the “Equity Incentive Plan”). This plan, along with its Israeli appendix, replaced all then-existing employee and consultants’ stock option plans.

The Equity Incentive Plan allows for the issuance of Restricted Stock Units (“RSUs”) as well as options. The options and RSUs generally vest over a period of four years. Options granted under the Equity Incentive Plan generally expire after six years from the date of grant. Options and RSUs cease vesting upon termination of the grantee’s employment or other relationship with the Company. The per share exercise price for options shall be no less than 100% of the fair market value per ordinary share on the date of grant. Any options and RSUs that are cancelled or not exercised within the option term become available for future grant.

On July 30, 2019, the shareholders of the Company approved an increase in the number of ordinary shares reserved for issuance under the 2016 Equity Incentive Plan and its Israeli Appendix to a total of 560,000. On August 31, 2022, the shareholders of the Company approved an increase in the number of ordinary shares reserved for issuance under the 2016 Equity Incentive Plan and its Israeli Appendix to a total of 1,225,000.

As of September 30, 2022, an aggregate of 440,309 ordinary shares of the Company were available for future grant under the Equity Incentive Plan.

Amended & Restated 2016 Non-Employee Director Equity Incentive Plan

In 1999, the Company adopted the 1999 Directors Stock Option Plan, and in 2008, the Company's shareholders approved an extension of the term of this plan through July 13, 2019. On December 15, 2006, the plan was extended through 2016. On December 22, 2016, shareholders approved the 2016 Non-Employee Director Equity Incentive Plan (the “Non-Employee Director Plan”). This plan, along with its Israeli appendix, replaced all existing directors' stock option plans.

The Non-Employee Director Plan allows for the issuance of RSUs as well as options. Each option and RSU granted under the Non-Employee Director Plan generally vests over a period of four years. Each option has an exercise price equal to the fair market value of the ordinary shares on the grant date of such option. Options granted under the Non-Employee Director Plan generally expire after six years from the date of grant. Options and RSUs cease vesting upon termination of the grantee's relationship with the Company.

On July 30, 2019, the shareholders of the Company approved an increase in the number of ordinary shares reserved for issuance under the Non-Employee Director Plan and its Israeli Appendix to a total of 57,500 ordinary shares. On August 31, 2022, the shareholders of the Company approved an increase in the number of ordinary shares reserved for issuance under the Non-Employee Director Plan and its Israeli Appendix to a total of 182,500 ordinary shares.

As of September 30, 2022, an aggregate of 55,367 ordinary shares of the Company remained available for future grants to non-employee directors.

-16-

CYREN LTD.

UNAUDITED NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

A summary of the Company’s employees and directors’ stock option activity under the plans is as follows:

(Unaudited and USD in thousands, except share prices)	Number of options	Weighted- average exercise price		Weighted- average remaining contractual term (years)	Aggregate intrinsic value
Outstanding at December 31, 2021	181,286	$	38.58	2.74	$	—
Granted	—	—		0	—
Exercised	—	—		0	—
Expired and forfeited	(35,388)	33.61		0	—
Outstanding at September 30, 2022	145,898	$	40.09	2.30	$	—
Options vested at September 30, 2022	143,934	$	40.24	2.29	$	—
Exercisable options at September 30, 2022	121,871	$	41.92	2.08	$	—

The aggregate intrinsic value in the tables above represents the total intrinsic value (the difference between the fair value of the Company’s ordinary shares as of the last day of each period and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on the last day of each period.

No options were exercised during the quarters ended September 30, 2022, and 2021, respectively, and the intrinsic value was zero as of September 30, 2022, and 2021, respectively.

For the quarter ended September 30, 2022, the Company did not grant options. The weighted-average grant date fair value of options granted to employees and directors during the quarter ended September 30, 2021, was $0.39.

As of September 30, 2022, the Company had $0.3 million of unrecognized compensation expense related to non-vested stock options granted to employees and directors, expected to be recognized over a remaining weighted-average period of 1.11 years.

The employee and directors’ options outstanding as of September 30, 2022, is separated into ranges of exercise prices as presented below:

Outstanding					Exercisable
Exercise price per share	Options outstanding	Weighted- average remaining contractual life in years	Weighted- average exercise price per share		Options exercisable	Weighted- average exercise price per share
$6.40 - $32.80	30,841	3.50	$	26.23	19,034	$	29.58
$34.00 - $40.00	24,001	1.20	$	38.54	21,294	$	39.07
$41.80 - $42.00	54,300	2.59	$	41.80	45,300	$	41.80
$46.00 - $64.00	36,756	1.60	$	50.23	36,243	$	50.22
Total employee and director options outstanding	145,898	2.30	$	40.09	121,871	$	41.92

-17-

CYREN LTD.

UNAUDITED NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

Options to non-employees and non-directors are disclosed as follows:

Issuance date	Options outstanding	Exercise price per share		Options exercisable	Exercisable through
January 24, 2017	1,250	$	40.00	1,250	Jan-23

The options vest and become exercisable at a rate of 1/16 of the options every three months.

As of September 30, 2022, the Company did not have any unrecognized compensation expense related to non-employee non-vested stock options.

A summary of the Company’s RSUs activity for employees, directors and non-employees under the plans is as follows:

	Number of RSUs	Weighted- Average Grant Date Fair Value
Awarded and unvested at December 31, 2021	344,307	$	18.20
Granted	713,050	1.74
Vested	(100,634)	20.57
Forfeited	(78,246)	17.18
Awarded and unvested at September 30, 2022	878,477	$	4.66

As of September 30, 2022, the Company had approximately $3.4 million of unrecognized compensation expense related to RSUs, expected to be recognized over a weighted-average period of 2.14 years.

The total share-based compensation expense related to all of the Company’s equity-based awards, recognized for the three and nine-month periods ended September 30, 2022, and 2021 was as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands)	2022		2021		2022		2021
Cost of revenues	$	43	$	76	$	152	$	166
Research and development	45		46		148		125
Sales and marketing	97		100		283		225
General and administrative	346		512		1,053		1,189
Total share-based compensation expense from continuing operations	$	531	$	734	$	1,636	$	1,705
Share-based compensation expense included in discontinued operations	(2)		18		11		52
Total share-based compensation expense	$	529	$	752	$	1,647	$	1,757

-18-

CYREN LTD.

UNAUDITED NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 7 - BASIC AND DILUTED NET LOSS PER SHARE

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands, except share amounts)	2022		2021		2022		2021
Numerator - continuing operations
(Loss) from continuing operations	$	(5,523)	$	(6,118)	$	(18,088)	$	(16,415)
Numerator - discontinued operations
Net income (loss) from discontinued operations	$	(575)	$	331	$	(6,929)	$	843
Denominator
Denominator for basic net loss per share weighted-average number of shares outstanding	7,822,424		3,899,502		6,858,937		3,700,789
Effect of diluting securities*	—		772,330		—		757,157
Denominator for diluted net loss per share - adjusted weighted average shares and assumed exercises	7,822,424		4,671,832		6,858,937		4,457,946
* For the discontinued operations, the total number of ordinary shares related to share-based compensation plans, aggregated to 613,377 and 683,156, for the three and nine months ended September 30, 2022, respectively, was excluded from the calculations of diluted loss per ordinary share since it would have an anti-dilutive effect.

NOTE 8 - SEGMENT AND GEOGRAPHIC INFORMATION

ASC 280, Segment Reporting, establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. The Company manages its business on the basis of one reportable segment and derives revenues from licensing of software and sales of support services, maintenance and technical support (see Note 1 - Organization for a brief description of the Company’s business).

The following presents total revenue by solutions offered by geographic area based on the billing address of the customer from continuing operations:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands)	2022		2021		2022		2021
United States	$	3,375	$	3,103	$	9,739	$	10,104
Germany	447		381		1,294		1,198
Europe-Other	768		756		2,509		2,412
Asia Pacific	581		401		1,432		1,480
Israel	544		849		1,967		2,610
Other	119		126		361		362
Total revenue	$	5,834	$	5,616	$	17,302	$	18,166

Major Customers

During each of the quarters ended September 30, 2022, and 2021, 23% and 22% of the Company’s revenues were derived from its largest customer, and no other customer accounted for more than 10% of total revenue.

Revenue Recognized from Beginning Deferred Revenue

During the quarters ended September 30, 2022, and 2021, $3.1 million and $3.4 million of revenue was recognized from deferred revenue as of the beginning of the period, respectively.

-19-

CYREN LTD.

UNAUDITED NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

During the nine months ended September 30, 2022, and 2021, $6.2 million and $8.9 million of revenue was recognized from deferred revenue as of the beginning of the period, respectively.

Remaining Performance Obligations

As of September 30, 2022, approximately $9.2 million of revenue is expected to be recognized from remaining performance obligations that are unsatisfied (or partially unsatisfied) for non-cancellable contracts. The Company expects to recognize revenue on approximately 26% of these remaining performance obligations during the remainder of 2022, approximately 51% in 2023, with the remainder recognized thereafter.

Revenue Generated by Customer Type

The following presents the Company's revenue by customer type from continuing operations:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands)	2022		2021		2022		2021
OEM/Embedded Security1	$	5,515	$	5,423	$	16,389	$	17,625
Enterprise/SMB2	287		193		881		541
Other	32		—		32		—
Total Revenue	$	5,834	$	5,616	$	17,302	$	18,166
1 This market represents customers who embed Cyren Threat Detection Services and Threat Intelligence Service feeds into their infrastructure and/or products to protect their customers and users.
2 In this market, Cyren provides enterprise as well as small and midsize business customers email security products and threat intelligence to help protect their employees, data and IP.

The following sets forth the Company’s long-lived tangible assets, net by geographic area from continuing operations:

(Unaudited and USD in thousands)	September 30, 2022		December 31, 2021
Israel	$	4,921	$	5,612
United States	541		1,017
Germany	219		669
Other	710		889
Total long-lived tangible assets	$	6,391	$	8,187

NOTE 9 - FINANCIAL EXPENSES, NET

The following sets forth the Company’s financial income (expense), net by expense type from continuing operations:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands)	2022		2021		2022		2021
Interest and accretion of discount	$	(213)	$	(331)	$	(640)	$	(960)
Foreign currency exchange differences, net	219		47		800		254
Other	(13)		2		(56)		1
Total financial expenses, net	$	(7)	$	(282)	$	104	$	(705)

-20-

CYREN LTD.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 10 - RELATED PARTIES

The following sets forth balances with related parties:

(Unaudited and USD in thousands)	September 30, 2022		December 31, 2021
Interest expense accrual – Convertible Debentures1	$	—	$	4
Long-term Convertible Debentures2	242		238
1 Related to the semi-annual interest payable due in March and September related to the Convertible Debentures entered into March 19, 2020. See Note 6 - Shareholders' Equity for further details.
2 Related to the Convertible Debentures entered into March 19, 2020. See Note 6 - Shareholders' Equity for further details.

The following sets forth transactions with related parties:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands)	2022		2021		2022		2021
Revenue1	$	25	$	—	$	75	$	—
Interest expense on Convertible Notes2	$	—	$	143	$	—	$	285
Interest expense on Convertible Debentures3	$	5	$	5	$	15	$	10
1 Related to a new OEM customer agreement signed in Q3 2021 where the Company and this customer share an investor that qualifies as a related party for each.
2 Related to the semi-annual interest payable due in June and December related to the Convertible Note entered into December 5, 2018. The principal was repaid in December 2021. See Note 6 - Shareholders' Equity for further details.
3 Related to the semi-annual interest payable due in March and September related to the Convertible Debentures entered into March 19, 2020. See Note 6 - Shareholders' Equity for further details.

-21-

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations and other parts of this Quarterly Report on Form 10-Q (“Quarterly Report”) describe the principal factors affecting the financial results, liquidity, capital resources and critical accounting estimates of Cyren LTD (“Cyren,” “we,” “our,” “us,” or the "Company"), and should be read in conjunction with the information contained in our consolidated financial statements and the notes thereto. The following discussion and analysis includes forward-looking statements that involve certain risks and uncertainties, including, but not limited to, those described in Item 1A. Risk Factors in our most recent Annual Report on Form 10-K (the “2021 Annual Report”). Our actual results may differ materially from those discussed below. See “Special Note Regarding Forward-Looking Statements” below.

OVERVIEW

Cyren was an early pioneer and leading innovator of cloud-delivered Software-as-a-Service (SaaS) cyber security solutions that protect businesses, their employees and customers against threats from email, files, and the Internet.

We believe our cloud-based approach to security sets us apart from other vendors in the market. Our security solutions are engineered around the fundamental belief that cyber security is a race against time – and the cloud best enables the speed, sophistication, and advanced automation needed to detect and block threats as they emerge. As more and more businesses move their data and applications to the cloud, they need a security provider that is able to keep pace.

Security threats are more prevalent and stealthier than ever. As cybercrime has become more sophisticated, every malware, phishing, and ransomware variant is unique, making it more difficult to detect attacks. While organizations have traditionally protected their users with gateway security appliances at the network perimeter, more frequent and evasive attacks combined with a more distributed workforce are reducing the effectiveness of this approach. Traditional appliances lack the real-time threat intelligence and processing power to detect emerging threats, and the growth of mobile devices and an increasingly distributed workforce means that more and more business is conducted outside of the traditional network perimeter. As a result, when new attacks appear in a matter of seconds, legacy cybersecurity products can leave companies vulnerable for hours, days or even weeks.

Cyren’s cloud security products and services fall into three categories:

•Cyren Threat Detection Services – these services detect a variety of threats in email, files, and from the Internet, and are embedded into products from the world’s leading email providers, cyber security vendors and managed service providers. Cyren Threat Detection Services include our Email Security Detection Engine, Malware Detection Engine, Web Security Engine, and Threat Analysis Service.

•Cyren Threat Intelligence Data – these products provide valuable threat intelligence data that can be used by enterprise or original equipment manufacturer (OEM) customers to support threat detection, threat hunting, and incident response. Cyren’s Threat Intelligence offerings include IP Reputation Intelligence, Phishing Intelligence, Malware Intelligence, and Zombie Intelligence.

•Cyren Enterprise Email Security Products – these include cloud-based solutions designed for enterprise customers and are sold either directly or through channel partners. Cyren Enterprise Email Security products include Cyren Email Security, a cloud-based secure email gateway, and Cyren Inbox Security, an anti-phishing product for Microsoft 365.

Cyren GmbH

On June 1, 2022, we entered into a definitive Sale and Purchase Agreement (the “SPA”) with Content Services Group GmbH to sell all the equity interests in our legacy secure email gateway business and wholly owned subsidiary, Cyren GmbH (the "Cyren GmbH Transaction").

On August 1, 2022, the Company completed the Cyren GmbH Transaction and received the initial €9.4 million payment (equivalent to $9.6 million as of the closing date). Under the terms of the SPA, a holdback in the amount of €0.7 million (the "Holdback Amount") is currently held in an escrow to satisfy certain claims. The Holdback Amount, less deductions for claims against the Company, if any, will be released to the Company no later than twelve months after the closing date.

-22-

Subsequent to the closing date, the Company paid approximately $1.4 million in expenses associated with the Cyren GmbH Transaction. Furthermore, the Company estimates that the final purchase price will be reduced by $0.4 million based on working capital and other adjustments and has accrued a current liability as of September 30, 2022. Beyond that, the Company is using the proceeds from the sale for working capital and general corporate purposes.

Key Opportunities and Challenges

Threat Landscape

The last several years have possibly experienced the greatest amount of dramatic global incidents directly related to malware and cyber threats since the advent of the Internet. From election hacks to global ransomware attacks, malware threats are at an all-time high. Phishing attacks have become increasingly common, and no company, large or small seems immune to these threats. Hackers have become more successful at monetizing these attacks, and as long as these activities prove lucrative, we expect these incidents to continue.

Cloud and Mobility

Businesses are experiencing a significant change in their IT strategies as they look to drive more business value, agility and better customer experiences, while cloud and mobility are becoming increasingly important, as evidenced by the following trends:

•Business Internet traffic continues to increase every year;

•Data and applications are increasingly moving to the cloud;

•More and more users are working remotely, particularly since the COVID-19 pandemic;

•Businesses continue to move away from traditional on-premise solutions;

•Mature and legacy on-premise deployments are reaching end of life and are increasingly being replaced by cloud and SaaS alternatives;

•IT security teams have experienced staffing shortages;

•Increasingly fast, sophisticated, expensive and high-profile attacks target organizations of all sizes;

•Compliance and regulatory mandates have increased;

•Cybercrime activity among commercial enterprises and nation states has heightened;

•Automation is increasingly considered critical to accelerating detection and protection; and

•Businesses need to simplify operations through vendor consolidation.

Given these trends, Cyren’s vision for 100% cloud security is compelling to IT security teams looking to protect their businesses in today’s cloud-centric mobile-first world.

Investments in Operations, Research and Development and Sales and Marketing

Our cost of revenues, research and development expenses, and sales and marketing expenses are all significant contributing factors to our operating losses. Over time, we expect we will increase utilization of our cloud infrastructure which we expect will provide the opportunity for improved gross margins. We believe that our investments in research and development are required in order to enhance and improve our solutions. In the future, we expect to lower the rate of research and development investment as a percentage of revenue. The return on our sales and marketing investment is tied to attracting new customers and enhancing our business with existing customers, thereby lowering the overall sales and marketing costs as a percent of revenues. We otherwise continue to monitor and, where possible, reduce expenses. We believe managing future headcount and expense growth will be key in improving our gross and operating margins over time given longer-term declining revenue trends.

-23-

Growing Our Enterprise Business

Cyren has prioritized growing its enterprise revenues. With the mid-2020 release of our anti-phishing solution, Cyren Inbox Security, we believe helping enterprises mitigate phishing attacks is our most significant revenue growth opportunity. Given the substantial size of the enterprise anti-phishing market, Cyren believes this new revenue stream has the potential to grow faster than our legacy OEM business. As this Cyren Inbox Security business grows, it has the potential to eventually contribute to a larger portion of our overall revenue, and longer term, we expect deferred revenue to increase and our operating results and cash flow to improve.

Components of our Operating Results

Revenue

We derive revenues from the sale of real-time cloud-based services for each of Cyren’s email security, threat detection services and threat intelligence data product offerings.

We sell all of our solutions as subscription services, either to OEMs and service providers or directly or indirectly to enterprises.

Cost of Revenue

Personnel costs, which consist of salaries, benefits, bonuses and share-based compensation for employees who operate our network and provide support services to our customers, as well as data center costs, are the most significant components of our cost of revenues. Other costs include third-party contractors, royalties for use of third-party technologies, amortization of intangibles and depreciation of data center equipment.

Operating Expenses

Our operating expenses consist of research and development, sales and marketing, and general and administrative expenses. Personnel costs, which consist of salaries, benefits, bonuses and share-based compensation, are the most significant component of our operating expenses. Operating expenses also include allocated overhead costs for facilities, IT and depreciation. We expect operating expenses to increase in absolute dollars as we continue to grow.

Research and Development

Research and development expenses consist primarily of personnel costs and outsourced engineering services. We believe these investments are crucial for our ability to continue to enhance the functionality of our services, as well as to develop and introduce new services to the market. Development costs related to internal use technology that supports our security services are capitalized on the balance sheet, while other development costs are expensed as they are incurred.

Sales and Marketing

Sales and marketing expenses primarily include personnel costs, sales commissions, marketing activities, and travel associated with sales and marketing. We market and sell our services worldwide through our sales organization and distribution channels. We capitalize sales commissions paid to internal sales personnel and amortize these expenses over an estimated period of benefit that reflects the expected future revenue streams. Sales and marketing expenses have increased in 2022 as we have enhanced our efforts to support further growth and invested in strategies related to new products launched in 2020. Newly hired sales personnel are typically not immediately productive, and therefore the increase in expenses we incur when adding personnel is not immediately accompanied by increased revenue and in some cases may not result in increased revenue if these new sales personnel are unsuccessful in becoming productive.

General and Administrative

General and administrative expenses consist primarily of personnel costs, audit fees, legal expenses, recruiting expenses and other general operating costs. We expect our general and administrative expenses to continue to grow in absolute dollars as we continue our business pursuits.

Other Income (Expense), net

Other income (expense), net generally consists of capital gain or loss from the sale of assets.

-24-

Financial Expenses, net

Financial expenses, net primarily consists of foreign exchange gains and losses, interest expense on our outstanding debt, and interest income earned on our cash and cash equivalents. In 2021 and 2022, these expenses also included income related to the accounting for a multi-year arrangement where a customer paid upfront the full contract value. This has been deemed a significant financing component under Accounting Standards Codification ("ASC") 606, Revenue Recognition.

Tax Benefit

Our tax benefit is derived primarily from income taxes in foreign jurisdictions in which we conduct business. We estimate income taxes in each of the jurisdictions in which we operate. This process involves determining income tax expense together with calculating the deferred income tax expense related to temporary differences resulting from the differing treatment of items for tax and accounting purposes. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. These temporary differences result in deferred tax assets and liabilities, which are included net as applicable within our balance sheets. For most of our recent years, we have incurred operating losses in Israel and the U.S., where we have recorded a full valuation allowance against our deferred tax assets in those jurisdictions.

-25-

RESULTS OF OPERATIONS

The following table sets forth our financial results for the three and nine months ended September 30, 2022, and 2021:

	Three Months Ended September 30,								Nine Months Ended September 30,
	2022				2021				2022				2021
(Unaudited and USD in thousands)	Amount		% of  Revenue*		Amount		% of  Revenue*		Amount		% of  Revenue*		Amount		% of  Revenue*
Revenues	$	5,834	100	%	$	5,616	100	%	$	17,302	100	%	$	18,166	100	%
Cost of revenues	3,015		52		3,311		59		9,677		56		9,941		55
Gross profit	2,819		48		2,305		41		7,625		44		8,225		45
Operating expenses:
Research and development, net	3,449		59		3,516		63		11,174		65		10,606		58
Sales and marketing	2,705		46		2,447		44		7,677		44		7,097		39
General and administrative	2,178		37		2,162		38		6,972		40		6,262		34
Total operating expenses	8,332		143		8,125		145		25,823		149		23,965		132
Operating loss	(5,513)		(94)		(5,820)		(104)		(18,198)		(105)		(15,740)		(87)
Other income (loss), net	(4)		—		4		—		(6)		—		(13)		—
Financial income (expenses), net	(7)		—		(282)		(5)		104		1		(705)		(4)
Loss before taxes on income	(5,524)		(95)		(6,098)		(109)		(18,100)		(105)		(16,458)		(91)
Tax benefit (expenses)	1		—		(20)		—		12		—		43		—
Net loss from continuing operations	$	(5,523)	(95)	%	$	(6,118)	(109)	%	$	(18,088)	(105)	%	$	(16,415)	(90)	%
Income (loss) from operations of discontinued operations, including loss on classification as held for sale	(575)		(10)	%	331		6	%	(6,929)		(40)	%	843		5	%
Net loss	$	(6,098)	(105)	%	$	(5,787)	(103)	%	$	(25,017)	(145)	%	$	(15,572)	(86)	%
* Percentages may not sum to 100% due to rounding.

As of September 30, 2022, we employed a total of 157 employees compared to 203 employees as of September 30, 2021. Effective August 1, 2022, 37 employees transitioned with Cyren GmbH as part of the Cyren GmbH Transaction.

Revenues

For the three months ended September 30, 2022, revenues increased $0.2 million, or 3.9%, compared to the same period in 2021. Revenue from our OEM business increased 1.7% resulting from growth of our Threat Intelligence Service solution. Revenue from our Enterprise business increased 48.7%, as our Cyren Inbox Security solution continued to generate year-over-year sales growth.

-26-

For the nine months ended September 30, 2022, revenues declined $0.9 million, or 4.8% compared to the same period in 2021. The decrease was mainly driven by a contract reduction from our largest customer (as first disclosed in our Form 10-Q for the quarter ended September 30, 2020), which was effective in the second quarter of 2021. The revenue impact of this contract reduction was $0.7 million. Additionally, revenue was adversely impacted by customer contract expirations or renewals at lower values coupled with the end of life of several legacy products that began during 2020. These declines were partially offset by new customers added in 2021 and 2022 in our Threat InDepth and Cyren Inbox Security products.

We released Cyren Inbox Security and Threat InDepth in the second quarter of 2020. Since these product launches, we have signed numerous new customer contracts representing over $3.8 million in estimated revenue over the lives of the contracts, but due to the timing, duration and ratable nature of the contracts, we did not recognize a material amount of related revenue for the nine months ended September 30, 2022.

Cost of Revenues

For each of the three and nine months ended September 30, 2022, cost of revenues declined $0.3 million, compared to the same periods in 2021. These declines were driven by favorable foreign exchange effects. Furthermore, certain hardware and software assets that support our products became fully depreciated during the periods. These declines were partially offset by an increase in costs associated with maintaining our data center operations.

As of September 30, 2022, we employed 23 employees within cost of revenues compared to 32 employees as of September 30, 2021. Effective August 1, 2022, nine employees transitioned with Cyren GmbH as part of the Cyren GmbH Transaction.

Operating Expenses

For the three months ended September 30, 2022, operating expenses increased $0.2 million, or 2.5%, compared to the same period in 2021, driven by an increase in marketing expenses of 0.3 million, or 10.5%, partially offset by a decline in research and development, net of $0.1 million, or 1.9%, while general and administrative expenses remained relatively flat. For the nine months ended September 30, 2022, operating expenses increased $1.9 million, or 7.8%, compared to the same period in 2021, the result of increases in general and administrative expenses of $0.7 million, or 11.3%, marketing expenses of $0.6 million, or 8.2%, and research and development of $0.6 million, or 5.4%.

Research and Development, Net

For the three months ended September 30, 2022, research and development declined $0.1 million, or 1.9%, compared to the same period in 2021. This decline was largely the result of lower compensation expenses. For the nine months ended September 30, 2022, research and development increased $0.6 million, or 5.4%, compared to the same period in 2021. This increase was driven primarily by the reduction in capitalization of technology development, which has the effect of increasing expenses.

As of September 30, 2022, we employed 78 employees within research and development compared to 111 employees as of September 30, 2021. Effective August 1, 2022, 23 employees transitioned with Cyren GmbH as part of the Cyren GmbH Transaction.

Sales and Marketing

For the three months ended September 30, 2022, sales and marketing expenses increased $0.3 million, or 10.5%, compared to the same period in 2021. For the nine months ended September 30, 2022, sales and marketing expenses increased $0.6 million, or 8.2%, compared to the same period in 2021. These increases were driven by our usage of global demand generation programs and consultants in an effort to increase sales and marketing efforts to support the growth of the Cyren Inbox Security product.

As of September 30, 2022, we employed 37 employees within sales and marketing compared to 33 employees as of September 30, 2021. None of our sales and marketing personnel transitioned with Cyren GmbH as part of the Cyren GmbH Transaction.

-27-

General and Administrative

For the three months ended September 30, 2022, general and administrative expenses increased 0.7% compared to the same period in 2021. For the nine months ended September 30, 2022, general and administrative expenses increased $0.7 million, or 11.3%, compared to the same period in 2021. This increase is primarily due to an increase in expenses for outside service, consultants and legal expenses, including costs associated with the Special Meeting of the Company's shareholders held in February 2022, which accounted for a $0.4 million increase year over year.

As of September 30, 2022, we employed 19 employees in general and administrative functions compared to 27 employees as of September 30, 2021. Effective August 1, 2022, five employees transitioned with Cyren GmbH as part of the Cyren GmbH Transaction .

Other Income (Expense), Net

For the three months ended September 30, 2022, other income, net decreased $8 thousand compared to the same period in 2021. For the nine months ended September 30, 2022, other income, net decreased $7 thousand, compared to the same period in 2021.

Financial Income (Expenses), Net

For the three months ended September 30, 2022, financial income (expenses), net, increased $0.3 million compared to the same period in 2021. For the nine months ended September 30, 2022, financial income (expenses), net, increased $0.8 million compared to the same period in 2021. These increases were driven by changes in foreign exchange rates, as the significant decline in the Euro (EUR) against the U.S. dollar (USD) during 2022 caused a reduction in certain of our EUR-denominated liabilities.

Income Taxes

Effective Corporate Tax Rates

For the three and nine months ended September 30, 2022, corporate tax rates and real capital gains tax in Israel were 23%.

Cyren GmbH was subject to German tax at a consolidated rate of approximately 30%.

Other non-Israeli subsidiaries are taxed according to the tax laws in their respective countries of residence.

We do not provide deferred tax liabilities when we intend to reinvest earnings of foreign subsidiaries indefinitely. As of September 30, 2022, we carried no undistributed earnings of foreign subsidiaries.

We may qualify as an “industrial company” within the definition of the Law for the Encouragement of Industry (Taxation) and, as such, we may be eligible for certain tax benefits, including, inter alia, special depreciation rates for machinery, equipment and buildings, amortization of patents, certain other intangible property rights and deduction of share issuance expenses.

Net Operating Loss Carryforwards

As of December 31, 2021, Cyren Ltd.’s operating loss carryforwards for tax purposes amounted to $114.2 million. Capital loss carryforwards amounted to $17.8 million which may be carried forward and offset against taxable income in the future, for an indefinite period.

As of December 31, 2021, Cyren Inc., our U.S. subsidiary, had net operating loss carryforwards of $42.8 million for federal tax purposes and $12.9 million for state tax purposes. These losses may offset any future U.S. taxable income of the U.S. subsidiary and will expire in the years 2022 through 2041.

Management currently believes that based upon its estimations for future taxable income, it is more likely than not that the deferred tax assets regarding the loss carryforwards will not be utilized in the foreseeable future. Thus, a valuation allowance was provided as of September 30, 2022, to reduce deferred tax assets to their realizable value.

-28-

LIQUIDITY AND CAPITAL RESOURCES

The Company has incurred losses since inception and expects to continue to incur losses for the foreseeable future. The Company intends to finance operating costs over the next twelve months through a combination of utilizing existing cash on hand, reducing operating spend, potentially divesting assets, and future issuances of equity and/or debt securities.

As of September 30, 2022, we had an accumulated deficit of $296.6 million, and cash and cash equivalents of $13.5 million. Current assets amounted to $17.9 million with current liabilities of approximately $13.9 million, resulting in working capital of $4.0 million.

For the nine months ended September 30, 2022, we recorded a net loss of $25.0 million. We have incurred losses since inception and expect to continue to incur losses for the foreseeable future. The current cash balance and historical trend of cash used in operations along with the lack of certainty regarding a future capital raise, provides substantial doubt about our ability to continue as a going concern for the next twelve months from the date of issuance of this Quarterly Report. The inability to borrow or raise sufficient funds on commercially reasonable terms, would have serious consequences to our financial condition and results of operations.

As previously discussed, on August 1, 2022, the Company completed the Cyren GmbH Transaction and received the initial €9.4 million payment (equivalent to $9.6 million as of the closing date). Under the terms of the SPA, a holdback in the amount of €0.7 million (the "Holdback Amount") is currently held in an escrow to satisfy certain claims. The Holdback Amount, less deductions for claims against the Company, if any, will be released to the Company no later than twelve months after the closing date.

Subsequent to the closing date, the Company has paid approximately $1.4 million in expenses associated with the Cyren GmbH Transaction. Furthermore, the Company estimates that the final purchase price will be reduced by $0.4 million based on working capital and other adjustments and has accrued a current liability as of September 30, 2022The Company is using the proceeds from the sale for working capital and general corporate purposes.

Our future capital requirements will depend on many factors, including, but not limited to our growth, market acceptance of our offerings, the timing and extent of spending to support our efforts to develop our products, and the expansion of sales and marketing activities based on our market opportunities. We expect to require additional equity or debt financing. If additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. If we issue additional equity securities to raise additional funds, further dilution to existing shareholders may occur. However, we cannot predict with certainty the outcome of our actions to generate liquidity, including the availability of additional financing. If we are unable to raise additional capital when desired, our business, financial condition, and results of operations could be adversely affected.

Cash Flow Analysis

Cash Flows from Operating Activities

Our primary source of cash provided by operating activities is revenues generated from sales of our services. Our primary uses of cash from operating activities include personnel costs, costs associated with maintaining our data centers and services necessary to support our customers.

Operating cash flow is calculated by adjusting our net loss for changes in working capital, as well as by excluding non-cash items such as: depreciation, non-cash operating lease expense, amortization expense of intangible assets, share-based compensation, impairment of research and development capitalization, amortization of deferred commissions, deferred taxes, net, non-cash interest expense on the convertible notes and Convertible Debentures.

-29-

For the nine months ended September 30, 2022, cash used in operating activities was $9.0 million as compared to cash used in operating activities of $12.5 million for the same period in 2021.

For the nine months ended September 30, 2022, the most significant factor affecting our operating cash flows was our net loss of $25.0 million, which included loss from discontinued operations of $6.9 million pertaining to the Cyren GmbH sale. Net cash used by operating activities also was the result of changes in operating lease liabilities of $1.7 million; prepaid expenses and other receivables of $1.3 million; deferred commissions of $1.2 million; and trade receivables of $0.9 million. This was partially offset by changes in deferred revenues of $6.1 million; amortization of intangible assets of $1.7 million; share-based compensation of $1.6 million; employee and payroll accruals, depreciation of $1.0 million and operating lease right-of-use asset of $0.9 million.

For the nine months ended September 30, 2021, the primary factors affecting our operating cash flows during the period were our net loss of $15.6 million, which included income from continuing operations of 0.8 million pertaining to the Cyren GmbH Transaction, and adjusted for non-cash items of $1.7 million of stock-based compensation expense, $1.0 million for amortization of our non-cash operating lease expense, $3.9 million for depreciation and amortization of our property, equipment, and intangible assets, and $0.6 million for amortization of deferred commissions. The primary drivers of the changes in operating assets and liabilities were a $1.2 million decrease in operating lease liabilities, a $0.6 million decrease in capitalization of deferred commissions, a $0.6 million decrease in prepaid expenses and other receivables, and a decrease in trade receivables of $2.6 million.

Cash Flows from Investing Activities

Cash used in investing activities primarily consists of payments related to capitalized technology, purchases of computer and network equipment to support our data center infrastructure, and furniture and equipment. The extent of these investments will be affected by our ability to expand relationships with existing customers, grow our customer base, as well as constraints on cash expenditures due to our financial position and the current economic environment.

For the nine months ended September 30, 2022, net cash used in investing activities was $7.2 million, consisting primarily of the proceeds from the Cyren GmbH sale.

For the nine months ended September 30, 2021, net cash used in investing activities was $0.4 million which primarily consisted of $0.3 million for capitalization of technology and $0.1 million used to purchase property and equipment.

Our capital expenditures over the last several years consisted primarily of continued investment in research and development and purchases of property and equipment to modernize and expand our data centers and to invest in our infrastructure to support new products and facilitate the Company's growth. We anticipate that capital expenditures for 2022 will be approximately $0.2 million.

Cash Flows from Financing Activities

The changes in cash flows from financing activities primarily relate to the issuance of the Convertible Debentures, and the issuance of ordinary shares and warrants to fund operations, offset by the repayment of debt upon maturity.

For the nine months ended September 30, 2022, net cash generated by financing activities was $10.9 million as we issued to several institutional investors in February 2022 in a private placement, 3,129,075 ordinary shares at a purchase price of $3.835 per share (or ordinary share equivalent) and associated warrants for net proceeds of approximately $10.9 million.

For the nine months ended September 30, 2021, net cash generated by financing activities was $12.6 million as we issued to several institutional investors in February 2021, in a registered direct offering 12,000,000 of our ordinary shares at a purchase price of $1.15 per share for net proceeds of approximately $12.6 million.

-30-

Financings

On February 16, 2021, we issued to several institutional investors in a registered direct offering, 600,000 of our ordinary shares at a purchase price of $23.00 per share for net proceeds of approximately $12.6 million. We used the proceeds from this offering for working capital and general corporate purposes. We also issued to the placement agent or its designees warrants to purchase up to 36,000 ordinary shares, representing 6% of the aggregate number of ordinary shares sold in the offering. The placement agent warrants have an exercise price equal to $28.75, or 125% of the offering price, per Ordinary Share and became exercisable on August 16, 2021, for five years from the effective date of the offering.

On September 17, 2021, we issued to several institutional investors in a private placement, 707,639 of our ordinary shares at a purchase price of $14.40 per share and warrants to purchase up to 707,639 ordinary shares at an exercise price of $12.00 per share for net proceeds of approximately $10.2 million. We used the gross proceeds from this offering for working capital and general corporate purposes. The warrants were exercisable immediately and terminate on March 17, 2025. We also issued to the placement agent or its designees warrants to purchase up to 42,459 ordinary shares, representing 6.0% of the aggregate number of ordinary shares sold in the offering. The placement agent warrants have an exercise price equal to $18.00 per share, or 125% of the offering price per share, were exercisable immediately and terminate on March 17, 2025.

On February 14, 2022, we issued to several institutional investors in a private placement, 3,129,075 ordinary shares (or ordinary share equivalents) and warrants to purchase up to 3,129,075 ordinary shares at a purchase price of $3.835 per share (or ordinary share equivalent) and associated warrant for net proceeds of approximately $12 million. We used the gross proceeds from this offering for working capital and general corporate purposes. The warrants were exercisable immediately, have an exercise price of $3.71 per ordinary share and terminate on August 16, 2027. We also issued to the placement agent or its designees warrants to purchase up to 187,745 ordinary shares, representing 6.0% of the aggregate number of ordinary shares sold in the offering. The placement agent warrants have an exercise price equal to $4.79 per share, or 125% of the offering price per share, were exercisable immediately and terminate on February 15, 2027.

Registration Statements

On September 21, 2018, we filed a shelf registration statement on Form F-3 with the SEC, which we converted to a Form S-3 on August 16, 2019. This registration statement enables us to issue debt securities, ordinary shares, warrants or subscription rights up to an aggregate amount of $50 million. Under the rules governing shelf registration statements, we will file a prospectus supplement with the SEC which describes the amount and type of securities being offered each time we issue securities under this registration statement. In November 2019, we issued shares as part of our rights offerings and in February 2021, we issued shares in the registered direct offering using our Form S-3 as described above. On July 28, 2022, we filed a replacement shelf registration statement on Form S-3 to replace the existing S-3 that expired on August 16, 2022.

Our market capitalization may limit our ability to raise additional capital in the public markets. Although we are currently eligible to use our Form S-3, we are limited to selling no more than one-third of our unaffiliated market capitalization, or public float, on Form S-3 in a 12-month period as our public float is below $75 million.

Outlook

The Company has incurred losses since inception and expects to continue to incur losses for the foreseeable future. The Company intends to finance operating costs over the next twelve months through a combination of utilizing existing cash on hand, reducing operating spend, potentially divesting assets, and future issuances of equity and/or debt securities.

The Company’s ability to continue as a going concern is dependent upon growing its business, obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations. While the Company intends to finance operating costs over the next twelve months through a combination of existing cash on hand, reducing operating spend, potentially divesting assets, and future issuances of equity and/or debt securities the Company cannot predict the availability of additional financing or the outcome of its actions to generate liquidity or maintain compliance with the Nasdaq Capital Market listing standards.

-31-

At a Special Meeting of the Company's shareholders held on February 7, 2022, the Company's shareholders approved a Reverse Share Split (including the relevant amendments to the Articles of Association of the Company) within a range of 1:4 to 1:20, and amendments to the Company's Articles of Association authorizing an increase in the Company's authorized share capital (and corresponding authorized ordinary shares) by up to NIS 216 million. The board of directors approved the implementation of a one-for-twenty Reverse Share Split and an increase in the Company's authorized share capital by NIS 216 million to NIS 240 million. The Reverse Share Split was effective on February 8, 2022, and the Company’s ordinary shares began trading on a split-adjusted basis on February 9, 2022. Following the Reverse Share Split and increase in authorized share capital, the total number of ordinary shares that the Company is authorized to issue is 80 million shares. While the Company was able to regain compliance with the Nasdaq minimum bid price requirement in February 2022 following the effectiveness of the Reverse Share Split, there can be no assurance that the Company will continue to meet the Nasdaq listing requirements. The inability to remain listed on Nasdaq may make it difficult for us to raise additional capital.

Over the past several years, the Company has devoted most of its effort to research and development and increasing revenues through additional investments in sales and marketing. For the nine months ended September 30, 2022, the Company generated a net loss of $25.0 million and a negative cash flow from operating activities of $9.0 million. For the year ended December 31, 2021, the Company recorded a net loss of $23.0 million and a negative cash flow from operating activities of $16.5 million. The Company has incurred losses since inception and expects to continue to incur losses for the foreseeable future.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our significant accounting policies are discussed in Note 2 - Significant Accounting Policies to our consolidated financial statements included in the Company’s 2021 Annual Report. There have been no significant changes to these policies for the three months ended September 30, 2022, except as described in Note 2 - Significant Accounting Policies to our condensed consolidated financial statements in this Quarterly Report. The critical accounting policies requiring estimates, assumptions, and judgments that we believe have the most significant impact on our consolidated financial statements are described in Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our 2021 Annual Report.

Please refer to Note 2 - Significant Accounting Policies for a full description of recent accounting pronouncements.

Goodwill represents the excess of the purchase price over the estimated fair value of net assets of a business acquired in a business combination. Under ASC Topic 350, Intangibles - Goodwill and Other ("ASC 350"), goodwill is not amortized, but rather is subject to impairment test at least annually. The Company performs an annual impairment test as of December 31 of each year, or more frequently if events or changes in circumstances indicate the carrying value may not be recoverable. Goodwill is tested for impairment at the reporting unit level by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the reporting unit does not pass the qualitative assessment, the Company carries out a quantitative test for impairment of goodwill by comparing the fair value of the reporting unit with the carrying amount of the reporting unit that includes goodwill. The Company may bypass the qualitative assessment and proceed directly to performing the quantitative goodwill impairment test.

The Company operates in one operating segment, and this segment comprises its only reporting unit.

December 31, 2021, 2020, no impairment losses were identified. For the three and nine months ended September 30, 2022, refer to Note 3.

It is possible that changes in circumstances existing at the measurement date or at other times in the future, or in the numerous estimates associated with management’s judgments, assumptions and estimates made in assessing the fair value of our goodwill, could result in an impairment charge of a portion or all of our goodwill. If the Company recorded an impairment charge, its financial position and results of operations would be adversely affected. For additional information, see "Risk Factors" in Item 1A of Part II of this report. We will continue to monitor certain events that impact our operations to determine if an interim assessment of goodwill impairment should be performed prior to the next required assessment date of December 31, 2022.

-32-

RUSSIAN INVASION OF UKRAINE

We maintain sales operations, employees, and customers located in multiple countries. We have contractors in Ukraine that assist in our operations group which support our products. The ongoing military conflict between Ukraine and Russia has resulted in minimal interruption of our operations in Ukraine and we are developing alternative plans should our contractors not be available for a period of time. While the precise effect of the ongoing military conflict and the sanctions on the Russian and global economies remains uncertain, should tensions continue to increase, financial markets may continue to experience significant volatility as well as economic and security consequences.

While as of the date of this Quarterly Report there have not been any material impacts from the above-mentioned matter in our consolidated financial statements, we are continuously monitoring the developments to assess any potential future impacts that may arise as a result of the ongoing crisis.

Other potential consequences include, but are not limited to, growth in the number of popular uprisings in the region, increased political discontent, especially in the regions most affected by the conflict or economic sanctions, increase in cyberterrorism activities and attacks, displacement of persons to regions close to the areas of conflict and an increase in the number of refugees fleeing across Europe, among other unforeseen social and humanitarian effects.

A protracted conflict between Ukraine and Russia, any escalation or expansion of that conflict, and the financial and economic sanctions and the above-mentioned adverse effect on the wider global economy and market conditions could, in turn, have a material adverse effect on our business, financial condition and results of operations

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

[Not required for smaller reporting companies.]

Special Note Regarding Forward-Looking Statements

This Quarterly Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements concern expectations, beliefs, projections, plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. We urge you to consider that statements which use the terms “anticipate,” “believe,” “expect,” “plan,” “intend,” “estimate,” “will” and similar expressions are intended to identify forward-looking statements. Specifically, this Quarterly Report contains forward-looking statements regarding:

•our expectations regarding our future profitability and revenue growth;

•our expectations regarding increases in cost of revenue and operating expenses, including as a result of our anticipated investments in R&D;

•our expectation to lower the rate of R&D investment as a percentage of revenue in the future and to drive more revenue from existing solutions rather than by adding new solutions;

•our expectations regarding reducing the historical rate of headcount growth and its resulting impact on our gross and operating margins over time;

•our expectations regarding growth of our enterprise business and its expected impact on our business, including its contribution to our cash flow and return on investment;

•our expectations regarding our ability to raise additional capital or issue more debt;

•our expectations regarding our capital expenditures for 2022;

•our belief regarding the adequacy of our existing capital resources and other future measures to satisfy our expected liquidity requirements;

•our beliefs regarding our competitive position in the market in which we operate;

•our expectations regarding the regulatory environment of data privacy in the EU;

-33-

•our anticipated significant investments in R&D and promotion of our brand;

•our expectations regarding trends in the market for Internet security and technology industry;

•our expectations regarding existing and new threats, key challenges and opportunities in our industry and their impact on our business, including the impact of innovations in the technology industry;

•our expectations regarding the increase in utilization of our cloud infrastructure and the resulting impact on our gross margins;

•our expectations regarding continued and future customers that will contribute to our revenue, and the solutions we provide to such customers;

•our beliefs regarding factors that make our vision compelling to the IT security market;

•our expectations regarding the locations where we conduct our business;

These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. The most important factors that could prevent us from achieving our goals, and cause the assumptions underlying forward-looking statements and the actual results to differ materially from those expressed in or implied by those forward-looking statements include, but are not limited to, the following:

•our ability to continue as a going concern;

•our ability to execute our business strategy;

•our ability to successfully enhance our existing products and introduce new products;

•the commercial success of our products;

•lack of demand for our products, including actual or perceived decreases in levels of cyber attacks;

•our ability to manage our costs, indebtedness and avoid unanticipated liabilities and achieve profitability;

•our ability to grow our revenues, including the ability of existing products to drive sufficient revenue;

•our ability to raise additional capital or debt;

•our ability to attract new customers and increase revenue from existing customers;

•the impact of future impairments of goodwill or other assets;

•market acceptance of our existing and new products;

•our ability to adapt to changing technological requirements and shifting preferences of our customers;

•the impact of COVID-19;

•our ability to remain listed on The Nasdaq Stock Market (“Nasdaq”);

•loss of any of our large customers or contracts;

•adverse conditions in the national and global financial markets;

•the impact of currency fluctuations;

-34-

•political and other conditions that may limit our R&D activities;

•the impact of the ongoing military conflict between Ukraine and Russia or any further escalation or expansion;

•The impact of increased inflation;

•increased competition or our ability to anticipate or effectively react to competitive challenges;

•the ability of our brand awareness strategies to enhance our brand recognition;

•our ability to retain key personnel;

•performance of our OEM partners, service providers and resellers;

•our ability to successfully estimate the impact of regulatory matters;

•our ability to comply with applicable laws and regulations and the impact of changes in applicable laws and regulations, including tax legislation or policies;

•economic, regulatory, and political risks associated with our international operations;

•the impact of cyber attacks or a security breach of our systems;

•our ability to protect our brand name and intellectual property rights; and

•our ability to successfully estimate the impact of certain accounting and tax matters, including the effect on our company of adopting certain accounting pronouncements.

The foregoing list of important factors does not include all such factors, nor necessarily present them in order of importance. In addition, you should consult other disclosures made by the Company (such as in our other filings with the SEC or in company press releases) for other factors that may cause actual results to differ materially from those projected by the Company. Please refer to Part I. Item 1A. Risk Factors, of the 2021 Annual Report for additional information regarding factors that could affect our results of operations, financial condition and liquidity. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, including the securities laws of the United States, we undertake no obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances, or otherwise after the date hereof.

ITEM 4. CONTROLS AND PROCEDURES

MANAGEMENT'S EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

In order to ensure that the information we must disclose in our filings with the SEC is recorded, processed, summarized and reported on a timely basis, we have formalized our disclosure controls and procedures. Our principal executive officer and principal accounting officer have reviewed and evaluated the effectiveness of our disclosure controls and procedures, as defined in Securities and Exchange Act Rules 13a-15(e) and 15d-15(e) as of September 30, 2022. Based on such evaluation, such officers have concluded that, as of September 30, 2022, our disclosure controls and procedures were effective.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

There were no changes to our internal control over financial reporting, as defined in Securities and Exchange Act Rules 13a-15(f) and 15d-15(f), that occurred during the quarter ended September 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

-35-

PART II – OTHER INFORMATION.

ITEM 1A. RISK FACTORS

No material changes have transpired in our risk factors from those disclosed in Item 1A. Risk Factors of our 2021 Annual Report and in Item 1A. Risk Factors of our quarterly reports for the periods ended March 31, 2022, and June 30, 2022.

ITEM 6. EXHIBITS

Exhibit No.	Description of Exhibits
31.1	Certification by Chief Executive and Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification by Chief Executive and Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification by Chief Executive and Principal Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	Inline XBRL Instance Document.
101.SCH	Inline XBRL Taxonomy Extension Schema Document.
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

-36-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CYREN LTD.
November 14, 2022	/s/ Brett Jackson
	Brett Jackson Chief Executive and Principal Financial Officer
November 14, 2022	/s/ P. Brady Hayden
	P. Brady Hayden Vice President, Finance and Accounting Principal Accounting Officer

-37-

EX-31.1

Exhibit 31.1

CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Brett Jackson, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Cyren Ltd.

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2022
	By:	/s/ Brett Jackson
		Brett Jackson Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION BY THE CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Brett Jackson, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Cyren Ltd.

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2022
	By:	/s/ Brett Jackson
		Principal Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Cyren Ltd. (the “Company”) for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Brett Jackson, Chief Executive and Principal Financial Officer of the Company, does certify, pursuant to Section 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge:

1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.the information contained in the Report fairly presents, in all materials respects, the financial condition and results of operations of the Company.

Date: November 14, 2022
	By:	/s/ Brett Jackson
		Brett Jackson Chief Executive and Principal Financial Officer

XML

Cover - shares	9 Months Ended
	Sep. 30, 2022	Oct. 31, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	000-26495
Entity Registrant Name	CYREN LTD.
Entity Incorporation, State or Country Code	L3
Entity Address, Address Line One	10 Ha-Menofim St.
Entity Address, Address Line Two	5th Floor
Entity Address, City or Town	Herzliya
Entity Address, Country	IL
Entity Address, Postal Zip Code	4672561
City Area Code	011
Local Phone Number	972–9–863–6888
Title of 12(b) Security	Ordinary Shares, par value ILS 3.00 per share
Trading Symbol	CYRN
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		7,999,808
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0001084577
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false

XML

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash and cash equivalents	$ 13,520	$ 4,288
Trade receivables (net of allowances for credit losses of $97 and $118, respectively)	1,234	352
Deferred commissions	706	482
Prepaid expenses and other receivables	2,451	1,120
Current assets held for sale (Note 3)	0	1,082
Total current assets	17,911	7,324
LONG-TERM ASSETS:
Long-term deferred commissions	797	521
Long-term lease deposits and prepaid expenses	630	686
Operating lease right-of-use assets	5,265	6,207
Severance pay fund	740	921
Property and equipment, net	1,126	1,980
Intangible assets, net	1,750	3,499
Goodwill	6,518	11,598
Long-term assets held for sale (Note 3)	0	13,392
Total long-term assets	16,826	38,804
Total assets	34,737	46,128
CURRENT LIABILITIES:
Trade payables	1,228	1,059
Employees and payroll accruals	3,230	4,196
Accrued expenses and other liabilities ($0 and $4 attributable to related parties, respectively)	1,342	937
Operating lease liabilities, current	1,083	1,330
Operating lease liabilities	5,376
Deferred revenues	6,581	3,004
Current liabilities held for sale (Note 3)	439	2,180
Total current liabilities	13,903	12,706
LONG-TERM LIABILITIES:
Deferred revenues	2,590	72
Convertible Debentures ($242 and $238 attributable to related parties, respectively)	8,717	8,578
Long-term operating lease liabilities	4,293	5,749
Deferred tax liability, net	157	167
Accrued severance pay	833	983
Other liabilities	447	517
Long-term liabilities held for sale (Note 3)	0	3,528
Total long-term liabilities	17,037	19,594
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:
Ordinary shares nominal value ILS 3.00 par value; Authorized: 80,000,000 shares as of September 30, 2022 (Unaudited) and December 31, 2021; Issued and Outstanding: 7,999,808 and 4,532,943 shares as of September 30, 2022 (Unaudited) and December 31, 2021, respectively	6,890	3,759
Additional paid-in capital	293,555	283,577
Accumulated other comprehensive loss	0	(1,877)
Accumulated deficit	(296,648)	(271,631)
Total shareholders’ equity	3,797	13,828
Total liabilities and shareholders’ equity	$ 34,737	$ 46,128

XML

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) $ in Thousands	Sep. 30, 2022 USD ($) shares	Sep. 30, 2022 ₪ / shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2021 ₪ / shares
Statement of Financial Position [Abstract]
Net of allowances for credit losses | $	$ 97		$ 118
Accrued expenses and other liabilities attributable to related parties | $	0		4
Convertible debentures attributable to related parties | $	$ 242		$ 238
Ordinary shares, par value (in USD per share) | ₪ / shares		₪ 3.00		₪ 3.00
Ordinary shares, authorized (in shares) | shares	80,000,000		80,000,000
Ordinary shares, issued (in shares) | shares	7,999,808		4,532,943
Ordinary shares, outstanding (in shares) | shares	7,999,808		4,532,943

XML

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenues	$ 5,834	$ 5,616	$ 17,302	$ 18,166
Cost of revenues	3,015	3,311	9,677	9,941
Gross profit	2,819	2,305	7,625	8,225
Operating expenses:
Research and development, net	3,449	3,516	11,174	10,606
Sales and marketing	2,705	2,447	7,677	7,097
General and administrative	2,178	2,162	6,972	6,262
Total operating expenses	8,332	8,125	25,823	23,965
Operating loss	(5,513)	(5,820)	(18,198)	(15,740)
Other (expense) income, net	(4)	4	(6)	(13)
Financial income (expenses), net ($5 and $148 interest expense attributable to related parties for the three months ended September 30, 2022, and 2021, respectively)	(7)	(282)	104	(705)
Loss from continuing operations before taxes on income	(5,524)	(6,098)	(18,100)	(16,458)
Tax benefit (expense)	1	(20)	12	43
Net loss from continuing operations	(5,523)	(6,118)	(18,088)	(16,415)
Net income (loss) from discontinued operations	(575)	331	(6,929)	843
Net loss	$ (6,098)	$ (5,787)	$ (25,017)	$ (15,572)
Continuing operations, per basic share (in dollars per share)	$ (0.71)	$ (1.57)	$ (2.64)	$ (4.44)
Discontinued operations, basic (in dollars per share)	(0.07)	0.08	(1.01)	0.23
Basic and diluted net loss per share, basic (in dollars per share)	(0.78)	(1.48)	(3.65)	(4.21)
Continuing operations, per diluted share (in dollars per share)	(0.71)	(1.57)	(2.64)	(4.44)
Discontinued operations, diluted (in dollars per share)	(0.07)	0.07	(1.01)	0.19
Basic and diluted net loss per share, diluted (in dollars per share)	$ (0.78)	$ (1.50)	$ (3.65)	$ (4.25)
Weighted-average number of shares used in computing basic net loss per share for continuing operations (in shares)	7,822,424	3,899,502	6,858,937	3,700,789
Weighted-average numbers of shares used in computing diluted net loss per share in discontinued operations (in shares)	7,822,424	4,671,832	6,858,937	4,457,946

XML

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Financial expenses, net interest expense attributable to related parties	$ 5	$ 148

XML

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (6,098)	$ (5,787)	$ (25,017)	$ (15,572)
Other comprehensive loss:
Foreign currency translation adjustments	(203)	(351)	(1,225)	(838)
Comprehensive loss	$ (6,301)	$ (6,138)	$ (26,242)	$ (16,410)

XML

Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited) - USD ($) $ in Thousands		Total	Number of out standing ordinary shares	Share capital	Additional paid-in capital	Accumulated other comprehensive loss	[1]	Accumulated deficit
Balance (in shares) at Dec. 31, 2020			3,063,596
Beginning balance at Dec. 31, 2020		$ 12,037		$ 2,392	$ 258,962	$ (725)		$ (248,592)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares and warrants, net of costs (in shares)	[2]		600,000
Issuance of shares and warrants, net of costs	[2]	12,588		556	12,032
Restricted share units vested (in shares)			32,100
Restricted share units vested		0		30	(30)
Payment of interest in shares (in shares)			14,572
Payment of interest in shares		259		13	246
Share-based compensation related to employees, directors and consultants		457			457
Issuance of shares upon early conversion of a Convertible Debentures (in shares)			60,074
Issuance of shares upon early conversion of a Convertible Debentures		859		55	804
Other comprehensive loss		(659)				(659)
Net loss		(4,197)						(4,197)
Balance (in shares) at Mar. 31, 2021			3,770,342
Ending balance at Mar. 31, 2021		21,344		3,046	272,471	(1,384)		(252,789)
Balance (in shares) at Dec. 31, 2020			3,063,596
Beginning balance at Dec. 31, 2020		12,037		2,392	258,962	(725)		(248,592)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(15,572)
Balance (in shares) at Sep. 30, 2021			4,518,190
Ending balance at Sep. 30, 2021		20,767		3,745	282,749	(1,563)		(264,164)
Balance (in shares) at Mar. 31, 2021			3,770,342
Beginning balance at Mar. 31, 2021		21,344		3,046	272,471	(1,384)		(252,789)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Payment of interest in shares (in shares)			11,670
Payment of interest in shares		142		10	132
Share-based compensation related to employees, directors and consultants		548			548
Other comprehensive loss		172				172
Net loss		(5,588)						(5,588)
Balance (in shares) at Jun. 30, 2021			3,782,012
Ending balance at Jun. 30, 2021		16,618		3,056	273,151	(1,212)		(258,377)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares and warrants, net of costs (in shares)	[3]		707,639
Issuance of shares and warrants, net of costs	[3]	9,276		662	8,614
Restricted share units vested (in shares)			11,813
Restricted share units vested		0		11	(11)
Payment of interest in shares (in shares)			16,726
Payment of interest in shares		259		16	243
Share-based compensation related to employees, directors and consultants		752			752
Other comprehensive loss		(351)				(351)
Net loss		(5,787)						(5,787)
Balance (in shares) at Sep. 30, 2021			4,518,190
Ending balance at Sep. 30, 2021		20,767		3,745	282,749	(1,563)		(264,164)
Balance (in shares) at Dec. 31, 2021			4,532,943
Beginning balance at Dec. 31, 2021		13,828		3,759	283,577	(1,877)		(271,631)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares and warrants, net of costs (in shares)	[3]		760,757
Issuance of shares and warrants, net of costs	[3]	10,942		709	10,233
Restricted share units vested (in shares)			70,322
Restricted share units vested		0		9	(9)
Exercise of pre-funded warrants (in shares)			365,059
Exercise of pre-funded warrants		0		345	(345)
Issuance of whole shares in lieu of fractional shares due to reverse stock split (in shares)			15,589
Payment of interest in shares (in shares)			31,667
Payment of interest in shares		259		29	230
Share-based compensation related to employees, directors and consultants		630			630
Other comprehensive loss		(251)				(251)
Net loss		(6,483)						(6,483)
Balance (in shares) at Mar. 31, 2022			5,776,337
Ending balance at Mar. 31, 2022		18,925		4,851	294,316	(2,128)		(278,114)
Balance (in shares) at Dec. 31, 2021			4,532,943
Beginning balance at Dec. 31, 2021		13,828		3,759	283,577	(1,877)		(271,631)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(25,017)
Balance (in shares) at Sep. 30, 2022			7,999,808
Ending balance at Sep. 30, 2022		3,797		6,890	293,555	0		(296,648)
Balance (in shares) at Mar. 31, 2022			5,776,337
Beginning balance at Mar. 31, 2022		18,925		4,851	294,316	(2,128)		(278,114)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Restricted share units vested (in shares)			7,998
Exercise of pre-funded warrants (in shares)			2,003,259
Exercise of pre-funded warrants		2		1,873	(1,871)
Share-based compensation related to employees, directors and consultants		488			488
Other comprehensive loss		(771)				(771)
Net loss		(12,436)						(12,436)
Balance (in shares) at Jun. 30, 2022			7,787,594
Ending balance at Jun. 30, 2022		6,208		6,724	292,933	(2,899)		(290,550)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Restricted share units vested (in shares)			21,942
Payment of interest in shares (in shares)			190,272
Payment of interest in shares		259		166	93
Share-based compensation related to employees, directors and consultants		529			529
Other comprehensive loss		(203)				(203)
Realized foreign currency translation		3,102				3,102
Net loss		(6,098)						(6,098)
Balance (in shares) at Sep. 30, 2022			7,999,808
Ending balance at Sep. 30, 2022		$ 3,797		$ 6,890	$ 293,555	$ 0		$ (296,648)

[1] 1 Relates to foreign currency translation adjustments.

[2] 2 Net of issuance costs of $1,212

[3] 3 Net of issuance costs of $1,057

XML

Condensed Consolidated Statements of Changes in Shareholders’ Equity (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]
Issuance costs	$ 1,057	$ 1,212

XML

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (25,017)	$ (15,572)
Less: Income (loss) from discontinued operations	(6,929)	843
Net loss from continuing operations	(18,088)	(16,415)
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities from continuing operations:
(Gain) loss on disposal of property and equipment	(1)	17
Loss on termination of operating leases	13	0
Depreciation	1,042	1,532
Share-based compensation	1,647	1,705
Amortization of intangible assets	1,749	1,785
Amortization of deferred commissions	738	644
Operating lease right-of-use-asset	929	1,032
Interest on convertible notes	0	430
Interest and amortization of debt issuance costs on convertible debentures	520	523
Deferred taxes, net	(10)	(62)
Changes in assets and liabilities:
Trade receivables	(882)	(2,627)
Prepaid expenses and other receivables	(1,331)	(578)
Deferred commissions	(1,238)	(637)
Long-term lease deposits and prepaid expenses	19	(18)
Trade payables	597	(1,622)
Employees and payroll accruals, accrued expenses and other liabilities	(424)	2,012
Deferred revenues	6,095	137
Accrued severance pay, net	31	(48)
Operating lease liabilities	(1,703)	(1,196)
Other long-term liabilities	(70)	(390)
Net cash used in operating activities from continuing operations	(10,367)	(13,776)
Net cash provided by operating activities from discontinued operations	1,395	1,314
Net cash used in operating activities	(8,972)	(12,462)
Cash flows from investing activities:
Proceeds from sale of a business	8,076	0
Proceeds from sale of property and equipment	1	6
Capitalization of technology	0	(262)
Purchase of property and equipment	(177)	(466)
Net cash provided by (used in) investing activities from continuing operations	7,900	(722)
Net cash used in investing activities from discontinued operations	(709)	0
Net cash used in investing activities	7,191	(722)
Cash flows from financing activities:
Proceeds from issuance of ordinary shares and warrants, net of issuance costs	10,942	0
Proceeds from stock issuance, net of costs	0	21,864
Proceeds from pre-funded warrants exercised	2	0
Net cash provided by financing activities	10,944	21,864
Effect of exchange rate changes on cash, cash equivalents and restricted cash	0	(36)
Increase in cash, cash equivalents and restricted cash	9,163	8,644
Cash, cash equivalents and restricted cash at the beginning of the period	4,951	9,914
Cash, cash equivalents and restricted cash at the end of the period	14,114	18,558
Supplemental disclosure of non-cash transactions:
Purchase of property and equipment by credit	(11)	(25)
Operating lease right-of-use asset exchanged for lease obligations	88	0
Issuance of shares on early conversion of Convertible Debentures	0	859
Issuance of shares for payment of interest on Convertible Notes	518	143
Reconciliation of cash, cash equivalents and restricted cash as shown in the condensed consolidated statements of cash flow:
Cash and cash equivalents	13,520	16,304
Restricted cash included in long-term restricted lease deposits	594	501
Cash, cash equivalents and restricted cash included in assets held for sale		1,753
Total cash, cash equivalents and restricted cash	$ 14,114	$ 18,558

XML

Organization

9 Months Ended

Sep. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

ORGANIZATION

ORGANIZATION

Cyren Ltd. (henceforth “Cyren”) was incorporated under the laws of the State of Israel on February 10, 1991, and its legal form is a company limited by shares. Cyren listed its shares to the public on July 15, 1999, under the name Commtouch Software Ltd. and changed its legal name to Cyren Ltd. in January 2014. Cyren and its subsidiaries, unless otherwise indicated, are referred to in these condensed consolidated financial statements as the “Company.”

The Company is engaged in developing and marketing cyber security solutions to identify and protect threats in email and electronic files and from the Internet. The Company sells its cloud-based solutions worldwide, in both embedded and Software-as-a-Service (SaaS) models, to original equipment manufacturers (“OEM”), service providers and enterprises. The Company operates in one reportable segment, which constitutes its reporting unit.

Over the past several years, the Company has devoted substantially most of its effort to research and product development and increasing revenues through additional investments in sales & marketing.

The Company has incurred losses since inception and expects to continue to incur losses for the foreseeable future. The Company's accumulated deficit as of September 30, 2022, was $296.6 million and negative cash flows from operating activities during the nine month period ending September 30, 2022, was $9.0 million. At September 30, 2022, the Company’s cash and cash equivalents position was not sufficient to fund the Company’s planned operations for at least a year beyond the filing date of the condensed consolidated financial statements. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due.

The Company intends to finance operating costs over the next twelve months through a combination of utilizing existing cash on hand, reducing operating spend, potentially divesting assets, and future issuances of equity and/or debt securities.

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business.

The condensed consolidated financial statements for the three and nine months ended September 30, 2022, do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

On February 10, 2022, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company issued and sold, in a private placement, an aggregate of 760,757 ordinary shares, pre-funded warrants to purchase up to 2,368,318 ordinary shares and ordinary warrants to purchase up to 3,129,075 ordinary shares for aggregate gross proceeds of approximately $12 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The purchase price of each ordinary share and associated ordinary warrant was $3.835 and the purchase price of each pre-funded warrant and associated ordinary warrant was $3.834. The ordinary warrants have an exercise price of $3.71, became exercisable upon issuance and expire on August 16, 2027. The pre-funded warrants have an exercise price of $0.001 and became exercisable upon issuance until exercised in full. The closing of the private placement occurred on February 14, 2022. The proceeds of the offering have been and continue to be used for working capital and general corporate purposes.

On June 1, 2022, the Company entered into a definitive Sale and Purchase Agreement (the “SPA”) with Content Services Group GmbH to sell all the equity interests in the Company’s legacy secure email gateway business and wholly owned subsidiary, Cyren GmbH (the “Cyren GmbH Transaction”). Pursuant to the SPA, the purchase price was €10.0 million in cash, subject to customary post-closing adjustments. Refer to Note 3 - Assets Held for Sale and Discontinued Operations for additional information.

On August 1, 2022, the Company completed the Cyren GmbH Transaction and received the initial €9.4 million payment (equivalent to $9.6 million as of the closing date). Under the terms of the SPA, a holdback in the amount of €0.7 million (the "Holdback Amount") is currently held in an escrow to satisfy certain claims. The Holdback Amount,

less deductions for claims against the Company, if any, will be released to the Company no later than twelve months after the closing date.

Subsequent to the closing date, the Company paid approximately $1.4 million in expenses associated with the Cyren GmbH Transaction. Furthermore, the Company estimates that the final purchase price will be reduced by $0.4 million based on working capital and other adjustments and has accrued a current liability as of September 30, 2022. Beyond that, the Company is using the proceeds from the sale for working capital and general corporate purposes.

On May 5, 2022, the Company formed a new German subsidiary, Cyren Germany GmbH, which has assumed a portion of Cyren GmbH's former operations as of the closing of the Cyren GmbH Transaction, including a datacenter and shared services center for the Company. Cyren Germany GmbH began operations in August 2022.

XML

Significant Accounting Policies

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES

Interim Financial Statements

The accompanying consolidated balance sheet as of September 30, 2022, the consolidated statements of operations, the consolidated statements of comprehensive loss for the three and nine months ended September 30, 2022, and 2021, and the consolidated statements of cash flows for the nine months ended September 30, 2022, and 2021, as well as the statement of changes in shareholders’ equity for the three and nine months ended September 30, 2022, are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the "SEC") regarding interim financial reporting. In management’s opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company’s financial position as of September 30, 2022, as well as its results of operations for the three and nine months ended September 30, 2022, and 2021 and cash flows for the nine months ended September 30, 2022, and 2021. The results of operations for the three and nine months ended September 30, 2022, are not necessarily indicative of the results to be expected for the year ending December 31, 2022, or for other interim periods or for future years.

Significant Accounting Policies

The accompanying unaudited interim consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Annual Report”) filed with the SEC on March 24, 2022.

Other than the change described below in Recently Issued and Adopted Pronouncements, there have been no changes to the significant accounting policies described in the 2021 Annual Report that have had a material impact on the unaudited interim consolidated financial statements and related notes.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the Company's consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities including goodwill impairment and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Discontinued Operations

A component of an entity that is disposed of by sale or abandonment is reported as discontinued operations if the transaction represents a strategic shift that will have a major effect on an entity's operations and financial results. Assets and liabilities of the discontinued operations are aggregated and reported separately in the Condensed Consolidated Balance Sheet, including the comparative prior year period. The results of discontinued operations are aggregated and presented separately in the Condensed Consolidated Statement of Operations. The disposed component cash flows are reflected as cash flows from discontinued operations within the Company’s Condensed Consolidated Statements of Cash Flows for each period presented. The Cyren GmbH Transaction was accounted for as discontinued operations and is presented in the Condensed Consolidated Balance Sheets as assets and liabilities held for sale. The results of discontinued operations are presented separately in the Condensed Consolidated Statements of Operation as discontinued operations.

Goodwill

Goodwill represents the excess of the purchase price over the estimated fair value of net assets of a business acquired in a business combination. Under ASC Topic 350, Intangibles - Goodwill and Other ("ASC 350"), goodwill is not amortized, but rather is subject to impairment test at least annually. The Company performs an annual impairment test as of December 31 of each year, or more frequently if events or changes in circumstances indicate the carrying value may not be recoverable. Goodwill is tested for impairment at the reporting unit level by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the reporting unit does not pass the qualitative assessment, the Company carries out a quantitative test for impairment of goodwill by comparing the fair value of the reporting unit with the carrying amount of the reporting unit that includes goodwill. The Company may bypass the qualitative assessment and proceed directly to performing the quantitative goodwill impairment test.

The Company operates in one operating segment, and this segment comprises its only reporting unit.

For the year ended December 31, 2021, no impairment losses were identified. For the three and nine months ended September 30, 2022, refer to Note 3 - Assets Held for Sale and Discontinued Operations.

Recently Issued and Adopted Pronouncements

In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-06, ASC Subtopic 470-20 Debt—Debt with Conversion and Other Options and ASC 815-40 Hedging—Contracts in Entity’s Own Equity. The standard reduced the number of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company early adopted this new guidance January 1, 2022. The adoption of ASU 2020-06 did not have a material impact on the consolidated financial statements.

XML

Assets Held for Sale and Discontinued Operations

9 Months Ended

Sep. 30, 2022

Discontinued Operations and Disposal Groups [Abstract]

ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS

ASSETS HELD FOR SALE AND DISCONTINUED OPERATIONS

As a result of the Cyren GmbH Transaction, the Company recorded certain assets as held for sale in its Condensed Consolidated Balance Sheet as of December 31, 2021. Additionally, the Company has recorded a loss on classification as held for sale in its Consolidated Condensed Statements of Operations for the three and nine months ended September 30, 2022, and 2021. Furthermore, the Company estimates that the final purchase price will be reduced by $0.4 million based on working capital and other adjustments and has accrued a current liability as of September 30, 2022. Refer to Note 1 - Organization for additional information.

The following assets and liabilities allocated to the discontinued operation are reflected as assets and liabilities of discontinued operations in the Company’s Consolidated Balance Sheet for the period presented. The major classes of assets and liabilities included as part of discontinued operations as of December 31, 2021, are presented in the following table:

(USD in thousands, except share and per share amounts)	December 31, 2021
Assets held for sale
Cash and cash equivalents	$	14
Trade receivables (net of allowances for credit losses of $19 and $40, respectively)	447
Deferred commissions	500
Prepaid expenses and other receivables	121
Long-term deferred commissions	412
Long-term lease deposits and prepaid expenses	123
Operating lease right-of-use assets	3,073
Property and equipment, net	203
Intangible assets, net	805
Goodwill	8,776
Total assets held for sale	$	14,474
Liabilities held for sale
Trade payables	$	16
Employees and payroll accruals	218
Accrued expenses and other liabilities	18
Operating lease liabilities	288
Deferred revenues - current	1,640
Deferred revenues - long-term	413
Long-term operating lease liabilities	2,875
Deferred tax liability, net	240
Total liabilities held for sale	$	5,708

The following details the Company's results of discontinued operations.

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands, except share and per share amounts)	2022		2021		2022		2021
Revenues	$	441	$	1,845	$	3,397	$	5,661
Cost of revenues	88		421		870		1,391
Gross profit	353		1,424		2,527		4,270
Operating expenses:
Research and development, net	139		584		1,140		1,854
Sales and marketing	19		338		484		1,057
General and administrative	36		174		371		539
Total operating expenses	194		1,096		1,995		3,450
Operating gain	159		328		532		820
Other income (expense), net	(34)		1		(33)		1
Financial expenses, net	(505)		(38)		(517)		(116)
Income (loss) from discontinued operations before taxes on income	(380)		291		(18)		705
Loss on sale	(195)		—		(6,985)		—
Total income (loss) from discontinued operations before taxes on income	(575)		291		(7,003)		705
Tax benefit	—		40		74		138
Net income (loss) from discontinued operations	(575)		331		(6,929)		843

The following table presents the loss associated with the sale, presented in the results of discontinued operations:

Gross purchase price	$	10,264
Transaction costs	(1,422)
Provision	(439)
Net assets sold	(12,286)
Realized foreign currency translation adjustments	(3,102)
Total net loss on divestiture	$	(6,985)

XML

Leases

9 Months Ended

Sep. 30, 2022

Leases [Abstract]

LEASES

LEASES

The Company accounts for leases according to ASC 842, Leases. The Company determines if an arrangement is a lease and the classification of that lease at inception. Right-of-use (“ROU”) assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. For leases with terms greater than 12 months, the Company records the ROU asset and liability at commencement date based on the present value of lease payments according to their term.

The Company uses incremental borrowing rates based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. The ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expenses are recognized on a straight-line basis over the lease term.

In addition, the carrying amount of the ROU and lease liabilities are remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset.

The Company elected the practical expedient for lease agreements with a term of twelve months or less and does not recognize ROU assets and lease liabilities in respect of those agreements. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.

The Company has various operating leases for office space and vehicles that expire through 2028. Below is a summary of the Company’s operating ROU assets and operating lease liabilities as of September 30, 2022:

	(Unaudited and USD in thousands)
Operating lease right-of-use assets	$	5,265
Operating lease liabilities, current	1,083
Operating lease liabilities long-term	4,293
Total operating lease liabilities	$	5,376

Minimum lease payments for the Company’s ROU assets over the remaining lease periods as of September 30, 2022, adjusted for discontinued operations, are as follows:

Year ended September 30,	(Unaudited and USD in thousands)
2022	$	314
2023	1,280
2024	1,127
2025	1,058
2026	1,001
Thereafter	1,141
Total undiscounted lease payments	$	5,921
Less: Interest	545
Present value of lease liabilities	$	5,376

Premises rent expense from continued operations was $430 and $574 for the three months ended September 30, 2022, and 2021, respectively, and $1,469 and $1,780 for the nine months ended September 30, 2022, and 2021, respectively.

During the quarter ended September 30, 2022, the Company subleased one real estate property as lessor, however this lease terminated in July 2022. Sublease receipts were $10 and $167 for the three months ended September 30, 2022 and 2021, respectively, and $202 and $496 for the nine months ended September 30, 2022 and 2021, respectively.

The weighted-average remaining lease terms and discount rates for all operating leases were as follows as of September 30, 2022:

Weighted-average remaining lease term (years)	5.1
Weighted-average discount rate	4.10	%

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

The Company, which was incorporated in Israel, has partially financed its research and development expenditures under programs sponsored by the Israel Innovation Authority (“IIA”) for the support of certain research and development activities conducted in Israel.

Since the Company's inception through 2018, the Company received $6.4 million of participation payments from the IIA in connection with specific research and development. Of this amount, $2.6 million was subject to repayment to the IIA through royalties related to product sales as of September 30, 2022, and December 31, 2021. In return for the IIA’s participation in this program, the Company is committed to pay royalties at a rate of 3% of the program’s developed product sales, up to 100% of the amount of grants received plus interest at the annual LIBOR rate. For the three months ended September 30, 2022, and 2021, the Company recorded zero and $31 thousand, respectively, as cost of revenues with respect to royalties due to the IIA. For the nine months ended September 30, 2022, and 2021, the Company recorded zero and $90 thousand, respectively, as cost of revenues with respect to royalties due to the IIA.

The Company is not currently involved in any legal proceedings or claims.

XML

Shareholders’ Equity

9 Months Ended

Sep. 30, 2022

Stockholders' Equity Note [Abstract]

SHAREHOLDERS’ EQUITY

SHAREHOLDERS’ EQUITY

General

Ordinary shares confer upon their holders the right to receive notice to participate and vote in general shareholder meetings of the Company and to receive dividends, if declared.

On February 7, 2022, the Company held a Special Meeting of Shareholders (the “Special Meeting”). At the Special Meeting, the Company’s shareholders approved (i) an amendment to the Company’s Amended and Restated Articles of Association (the “Articles of Association”) to effect a reverse share split of the Company’s ordinary shares (the “Reverse Share Split”) at a ratio of not less than one-for-four and not more than one-for-twenty, with such ratio and the implementation and timing of the Reverse Share Split to be determined by the Company’s board of directors in its sole discretion within thirty days of the Special Meeting and (ii) an increase in the authorized share capital by up to NIS 216.0 million to 240.0 million and an amendment to the Company’s Articles of Association accordingly.

Following the Special Meeting, on February 7, 2022, the board of directors of the Company approved a one-for-twenty Reverse Share Split and an increase in the Company’s authorized share capital by NIS 216.0 million, and the Articles of Association of the Company were amended accordingly. The Reverse Share Split became effective on February 9, 2022. Additionally, effective at the same time, the total number of ordinary shares the Company is authorized to issue after the effect of the Reverse Share Split is 80 million, the par value per ordinary share is NIS 3.00 and the authorized share capital of the Company is NIS 240.0 million.

Upon the effectiveness of the Reverse Share Split, every twenty ordinary shares were automatically combined and converted into one ordinary share. Appropriate adjustments were also made to all outstanding derivative securities of the Company, including all outstanding equity awards and warrants.

No fractional shares were issued in connection with the Reverse Share Split. Instead, all fractional shares (including shares underlying outstanding equity awards and warrants) were rounded up to the nearest whole ordinary share.

All the ordinary shares and per share data have been retroactively adjusted for the impact of the Reverse Share Split.

Issuance of Convertible Notes

On December 5, 2018, the Company issued $10.0 million aggregate principal amount of convertible notes in a private offering. The notes were unsecured, unsubordinated obligations of Cyren and carried a 5.75% interest rate, payable semi-annually in (i) 50% cash and (ii) 50% cash or ordinary shares at Cyren’s election. The notes had a 3-year term and matured in December 2021. The notes were issued with a conversion price of $3.90 per share which was subject to adjustment using a weighted-average ratchet mechanism based on the size and price of future equity offerings and the total shares outstanding. On November 7, 2019, Cyren announced the closing of a rights offering that raised gross proceeds of $8.0 million. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.73. On February 16, 2021, Cyren announced securities purchase agreements with several institutional investors for the purchase and sale, in a registered direct offering, of 12.0 million of the Company’s ordinary shares at a purchase price of $1.15 per share for net proceeds of $12.6 million. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.38. On September 17, 2021, the Company issued to several institutional investors in a private placement 14,152,779 ordinary shares at a purchase price of $0.72 per share and warrants to purchase up to 14,152,779 ordinary shares at an exercise price of $0.60 per share. As a result of this offering, the conversion price of the convertible notes was adjusted to $3.02 per share. In addition, the notes were subject to immediate conversion upon any change in control in the Company (or subject to repayment if the price in the change in control transaction is less than the conversion price).

The principal balance of $10.0 million on the convertible notes was repaid upon maturity on December 5, 2021. No further obligations remain with respect to the convertible notes.

The Company incurred no interest expense for the three and nine months ended September 30, 2022. The Company incurred interest expense of $0.1 million and $0.4 million for the three and nine months ended September 30, 2021.

Issuance of Convertible Debentures

In March 2020, the Company entered into purchase agreements with a select group of accredited investors for the purchase of $10.3 million aggregate principal amount of Convertible Debentures in a private placement. Upon the closing, the Company received approximately $9.4 million (net of $0.8 million in issuance expenses).

The debentures are unsecured, subordinated obligations of Cyren and carry a 5.75% interest rate per annum, payable semi-annually in cash or ordinary shares at Cyren’s election. The debentures have a four-year term and mature in March 2024, unless converted in accordance with their terms prior to maturity. The debentures have a conversion price of $15.00 per share and are convertible into 67 ordinary shares per $1.0 million principal amount of debentures. The conversion price is subject to adjustment based on the price and timing of future equity offerings and other customary adjustments. Upon the satisfaction of price and other conditions, Cyren has the right to force the conversion of the debentures.

In March 2021, the Company paid semi-annual interest payments totaling $0.3 million through the issuance of 14,572 shares of common stock. In September 2021, the Company paid semi-annual interest payments totaling $0.3 million through the issuance of 16,726 shares. In March 2022, the Company paid semi-annual interest payments totaling $0.3 million through the issuance of 31,667 shares of common stock. In September 2022, the Company paid semi-annual interest payments totaling $0.3 million through the issuance of 190,272 shares of common stock.

For the quarter ended March 31, 2021, two debenture holders converted a combined $1 million of principal plus interest of their debentures, which was a portion of their holdings. The principal and interest were paid through the issuance of 60,074 shares. There were no conversions for the quarter ended September 30, 2022.

The Company incurred interest expense of $176 thousand and $520 thousand for the three and nine months ended September 30, 2022, of which $48 thousand and $139 thousand was related to the amortization of debt issuance costs, respectively. The Company incurred interest expense of $180 thousand and $523 thousand for the three and nine months ended September 30, 2021, of which $44 thousand and $134 thousand was related to the amortization of debt issuance costs, respectively.

The Company had no accrued interest as of September 30, 2022, and $137 thousand as of December 31, 2021, respectively.

The principal balance of the Convertible Debentures as of September 30, 2022, was $8.7 million.

Amended and Restated 2016 Equity Incentive Plan

On December 22, 2016, the Company’s shareholders approved the 2016 Equity Incentive Plan (the “Equity Incentive Plan”). This plan, along with its Israeli appendix, replaced all then-existing employee and consultants’ stock option plans.

The Equity Incentive Plan allows for the issuance of Restricted Stock Units (“RSUs”) as well as options. The options and RSUs generally vest over a period of four years. Options granted under the Equity Incentive Plan generally expire after six years from the date of grant. Options and RSUs cease vesting upon termination of the grantee’s employment or other relationship with the Company. The per share exercise price for options shall be no less than 100% of the fair market value per ordinary share on the date of grant. Any options and RSUs that are cancelled or not exercised within the option term become available for future grant.

On July 30, 2019, the shareholders of the Company approved an increase in the number of ordinary shares reserved for issuance under the 2016 Equity Incentive Plan and its Israeli Appendix to a total of 560,000. On August 31, 2022, the shareholders of the Company approved an increase in the number of ordinary shares reserved for issuance under the 2016 Equity Incentive Plan and its Israeli Appendix to a total of 1,225,000.

As of September 30, 2022, an aggregate of 440,309 ordinary shares of the Company were available for future grant under the Equity Incentive Plan.

Amended & Restated 2016 Non-Employee Director Equity Incentive Plan

In 1999, the Company adopted the 1999 Directors Stock Option Plan, and in 2008, the Company's shareholders approved an extension of the term of this plan through July 13, 2019. On December 15, 2006, the plan was extended through 2016. On December 22, 2016, shareholders approved the 2016 Non-Employee Director Equity Incentive Plan (the “Non-Employee Director Plan”). This plan, along with its Israeli appendix, replaced all existing directors' stock option plans.

The Non-Employee Director Plan allows for the issuance of RSUs as well as options. Each option and RSU granted under the Non-Employee Director Plan generally vests over a period of four years. Each option has an exercise price equal to the fair market value of the ordinary shares on the grant date of such option. Options granted under the Non-Employee Director Plan generally expire after six years from the date of grant. Options and RSUs cease vesting upon termination of the grantee's relationship with the Company.

On July 30, 2019, the shareholders of the Company approved an increase in the number of ordinary shares reserved for issuance under the Non-Employee Director Plan and its Israeli Appendix to a total of 57,500 ordinary shares. On August 31, 2022, the shareholders of the Company approved an increase in the number of ordinary shares reserved for issuance under the Non-Employee Director Plan and its Israeli Appendix to a total of 182,500 ordinary shares.

As of September 30, 2022, an aggregate of 55,367 ordinary shares of the Company remained available for future grants to non-employee directors.

A summary of the Company’s employees and directors’ stock option activity under the plans is as follows:

(Unaudited and USD in thousands, except share prices)	Number of options	Weighted- average exercise price		Weighted- average remaining contractual term (years)	Aggregate intrinsic value
Outstanding at December 31, 2021	181,286	$	38.58	2.74	$	—
Granted	—	—		0	—
Exercised	—	—		0	—
Expired and forfeited	(35,388)	33.61		0	—
Outstanding at September 30, 2022	145,898	$	40.09	2.30	$	—
Options vested at September 30, 2022	143,934	$	40.24	2.29	$	—
Exercisable options at September 30, 2022	121,871	$	41.92	2.08	$	—

The aggregate intrinsic value in the tables above represents the total intrinsic value (the difference between the fair value of the Company’s ordinary shares as of the last day of each period and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on the last day of each period.

No options were exercised during the quarters ended September 30, 2022, and 2021, respectively, and the intrinsic value was zero as of September 30, 2022, and 2021, respectively.

For the quarter ended September 30, 2022, the Company did not grant options. The weighted-average grant date fair value of options granted to employees and directors during the quarter ended September 30, 2021, was $0.39.

As of September 30, 2022, the Company had $0.3 million of unrecognized compensation expense related to non-vested stock options granted to employees and directors, expected to be recognized over a remaining weighted-average period of 1.11 years.

The employee and directors’ options outstanding as of September 30, 2022, is separated into ranges of exercise prices as presented below:

Outstanding					Exercisable
Exercise price per share	Options outstanding	Weighted- average remaining contractual life in years	Weighted- average exercise price per share		Options exercisable	Weighted- average exercise price per share
$6.40 - $32.80	30,841	3.50	$	26.23	19,034	$	29.58
$34.00 - $40.00	24,001	1.20	$	38.54	21,294	$	39.07
$41.80 - $42.00	54,300	2.59	$	41.80	45,300	$	41.80
$46.00 - $64.00	36,756	1.60	$	50.23	36,243	$	50.22
Total employee and director options outstanding	145,898	2.30	$	40.09	121,871	$	41.92

Options to non-employees and non-directors are disclosed as follows:

Issuance date	Options outstanding	Exercise price per share		Options exercisable	Exercisable through
January 24, 2017	1,250	$	40.00	1,250	Jan-23

The options vest and become exercisable at a rate of 1/16 of the options every three months.

As of September 30, 2022, the Company did not have any unrecognized compensation expense related to non-employee non-vested stock options.

A summary of the Company’s RSUs activity for employees, directors and non-employees under the plans is as follows:

	Number of RSUs	Weighted- Average Grant Date Fair Value
Awarded and unvested at December 31, 2021	344,307	$	18.20
Granted	713,050	1.74
Vested	(100,634)	20.57
Forfeited	(78,246)	17.18
Awarded and unvested at September 30, 2022	878,477	$	4.66

As of September 30, 2022, the Company had approximately $3.4 million of unrecognized compensation expense related to RSUs, expected to be recognized over a weighted-average period of 2.14 years.

The total share-based compensation expense related to all of the Company’s equity-based awards, recognized for the three and nine-month periods ended September 30, 2022, and 2021 was as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands)	2022		2021		2022		2021
Cost of revenues	$	43	$	76	$	152	$	166
Research and development	45		46		148		125
Sales and marketing	97		100		283		225
General and administrative	346		512		1,053		1,189
Total share-based compensation expense from continuing operations	$	531	$	734	$	1,636	$	1,705
Share-based compensation expense included in discontinued operations	(2)		18		11		52
Total share-based compensation expense	$	529	$	752	$	1,647	$	1,757

XML

Basic and Diluted Net Loss Per Share

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Basic and Diluted Net Loss Per Share

BASIC AND DILUTED NET LOSS PER SHARE

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands, except share amounts)	2022		2021		2022		2021
Numerator - continuing operations
(Loss) from continuing operations	$	(5,523)	$	(6,118)	$	(18,088)	$	(16,415)
Numerator - discontinued operations
Net income (loss) from discontinued operations	$	(575)	$	331	$	(6,929)	$	843
Denominator
Denominator for basic net loss per share weighted-average number of shares outstanding	7,822,424		3,899,502		6,858,937		3,700,789
Effect of diluting securities*	—		772,330		—		757,157
Denominator for diluted net loss per share - adjusted weighted average shares and assumed exercises	7,822,424		4,671,832		6,858,937		4,457,946
* For the discontinued operations, the total number of ordinary shares related to share-based compensation plans, aggregated to 613,377 and 683,156, for the three and nine months ended September 30, 2022, respectively, was excluded from the calculations of diluted loss per ordinary share since it would have an anti-dilutive effect.

XML

Segment and Geographic Information

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

SEGMENT AND GEOGRAPHIC INFORMATION

SEGMENT AND GEOGRAPHIC INFORMATION

ASC 280, Segment Reporting, establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. The Company manages its business on the basis of one reportable segment and derives revenues from licensing of software and sales of support services, maintenance and technical support (see Note 1 - Organization for a brief description of the Company’s business).

The following presents total revenue by solutions offered by geographic area based on the billing address of the customer from continuing operations:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands)	2022		2021		2022		2021
United States	$	3,375	$	3,103	$	9,739	$	10,104
Germany	447		381		1,294		1,198
Europe-Other	768		756		2,509		2,412
Asia Pacific	581		401		1,432		1,480
Israel	544		849		1,967		2,610
Other	119		126		361		362
Total revenue	$	5,834	$	5,616	$	17,302	$	18,166

Major Customers

During each of the quarters ended September 30, 2022, and 2021, 23% and 22% of the Company’s revenues were derived from its largest customer, and no other customer accounted for more than 10% of total revenue.

Revenue Recognized from Beginning Deferred Revenue

During the quarters ended September 30, 2022, and 2021, $3.1 million and $3.4 million of revenue was recognized from deferred revenue as of the beginning of the period, respectively.

During the nine months ended September 30, 2022, and 2021, $6.2 million and $8.9 million of revenue was recognized from deferred revenue as of the beginning of the period, respectively.

Remaining Performance Obligations

As of September 30, 2022, approximately $9.2 million of revenue is expected to be recognized from remaining performance obligations that are unsatisfied (or partially unsatisfied) for non-cancellable contracts. The Company expects to recognize revenue on approximately 26% of these remaining performance obligations during the remainder of 2022, approximately 51% in 2023, with the remainder recognized thereafter.

Revenue Generated by Customer Type

The following presents the Company's revenue by customer type from continuing operations:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands)	2022		2021		2022		2021
OEM/Embedded Security1	$	5,515	$	5,423	$	16,389	$	17,625
Enterprise/SMB2	287		193		881		541
Other	32		—		32		—
Total Revenue	$	5,834	$	5,616	$	17,302	$	18,166
1 This market represents customers who embed Cyren Threat Detection Services and Threat Intelligence Service feeds into their infrastructure and/or products to protect their customers and users.
2 In this market, Cyren provides enterprise as well as small and midsize business customers email security products and threat intelligence to help protect their employees, data and IP.

The following sets forth the Company’s long-lived tangible assets, net by geographic area from continuing operations:

(Unaudited and USD in thousands)	September 30, 2022		December 31, 2021
Israel	$	4,921	$	5,612
United States	541		1,017
Germany	219		669
Other	710		889
Total long-lived tangible assets	$	6,391	$	8,187

XML

Financial Expenses, Net

9 Months Ended

Sep. 30, 2022

Financial Services Costs [Abstract]

FINANCIAL EXPENSES, NET

FINANCIAL EXPENSES, NET

The following sets forth the Company’s financial income (expense), net by expense type from continuing operations:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands)	2022		2021		2022		2021
Interest and accretion of discount	$	(213)	$	(331)	$	(640)	$	(960)
Foreign currency exchange differences, net	219		47		800		254
Other	(13)		2		(56)		1
Total financial expenses, net	$	(7)	$	(282)	$	104	$	(705)

XML

Related Parties

9 Months Ended

Sep. 30, 2022

Related Party Transactions [Abstract]

RELATED PARTIES

RELATED PARTIES

The following sets forth balances with related parties:

(Unaudited and USD in thousands)	September 30, 2022		December 31, 2021
Interest expense accrual – Convertible Debentures1	$	—	$	4
Long-term Convertible Debentures2	242		238
1 Related to the semi-annual interest payable due in March and September related to the Convertible Debentures entered into March 19, 2020. See Note 6 - Shareholders' Equity for further details.
2 Related to the Convertible Debentures entered into March 19, 2020. See Note 6 - Shareholders' Equity for further details.

The following sets forth transactions with related parties:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands)	2022		2021		2022		2021
Revenue1	$	25	$	—	$	75	$	—
Interest expense on Convertible Notes2	$	—	$	143	$	—	$	285
Interest expense on Convertible Debentures3	$	5	$	5	$	15	$	10
1 Related to a new OEM customer agreement signed in Q3 2021 where the Company and this customer share an investor that qualifies as a related party for each.
2 Related to the semi-annual interest payable due in June and December related to the Convertible Note entered into December 5, 2018. The principal was repaid in December 2021. See Note 6 - Shareholders' Equity for further details.
3 Related to the semi-annual interest payable due in March and September related to the Convertible Debentures entered into March 19, 2020. See Note 6 - Shareholders' Equity for further details.

XML

Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Interim Financial Statements

Interim Financial Statements

The accompanying consolidated balance sheet as of September 30, 2022, the consolidated statements of operations, the consolidated statements of comprehensive loss for the three and nine months ended September 30, 2022, and 2021, and the consolidated statements of cash flows for the nine months ended September 30, 2022, and 2021, as well as the statement of changes in shareholders’ equity for the three and nine months ended September 30, 2022, are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the "SEC") regarding interim financial reporting. In management’s opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company’s financial position as of September 30, 2022, as well as its results of operations for the three and nine months ended September 30, 2022, and 2021 and cash flows for the nine months ended September 30, 2022, and 2021. The results of operations for the three and nine months ended September 30, 2022, are not necessarily indicative of the results to be expected for the year ending December 31, 2022, or for other interim periods or for future years.

Significant Accounting Policies

Significant Accounting Policies

The accompanying unaudited interim consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Annual Report”) filed with the SEC on March 24, 2022.

Other than the change described below in Recently Issued and Adopted Pronouncements, there have been no changes to the significant accounting policies described in the 2021 Annual Report that have had a material impact on the unaudited interim consolidated financial statements and related notes.

Use of Estimates

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the Company's consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities including goodwill impairment and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Discontinued Operations

Discontinued OperationsA component of an entity that is disposed of by sale or abandonment is reported as discontinued operations if the transaction represents a strategic shift that will have a major effect on an entity's operations and financial results. Assets and liabilities of the discontinued operations are aggregated and reported separately in the Condensed Consolidated Balance Sheet, including the comparative prior year period. The results of discontinued operations are aggregated and presented separately in the Condensed Consolidated Statement of Operations. The disposed component cash flows are reflected as cash flows from discontinued operations within the Company’s Condensed Consolidated Statements of Cash Flows for each period presented. The Cyren GmbH Transaction was accounted for as discontinued operations and is presented in the Condensed Consolidated Balance Sheets as assets and liabilities held for sale. The results of discontinued operations are presented separately in the Condensed Consolidated Statements of Operation as discontinued operations.

Goodwill

Goodwill

Goodwill represents the excess of the purchase price over the estimated fair value of net assets of a business acquired in a business combination. Under ASC Topic 350, Intangibles - Goodwill and Other ("ASC 350"), goodwill is not amortized, but rather is subject to impairment test at least annually. The Company performs an annual impairment test as of December 31 of each year, or more frequently if events or changes in circumstances indicate the carrying value may not be recoverable. Goodwill is tested for impairment at the reporting unit level by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the reporting unit does not pass the qualitative assessment, the Company carries out a quantitative test for impairment of goodwill by comparing the fair value of the reporting unit with the carrying amount of the reporting unit that includes goodwill. The Company may bypass the qualitative assessment and proceed directly to performing the quantitative goodwill impairment test.

The Company operates in one operating segment, and this segment comprises its only reporting unit.

For the year ended December 31, 2021, no impairment losses were identified. For the three and nine months ended September 30, 2022, refer to Note 3 - Assets Held for Sale and Discontinued Operations.

Recently Issued and Adopted Pronouncements

Recently Issued and Adopted Pronouncements

In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-06, ASC Subtopic 470-20 Debt—Debt with Conversion and Other Options and ASC 815-40 Hedging—Contracts in Entity’s Own Equity. The standard reduced the number of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company early adopted this new guidance January 1, 2022. The adoption of ASU 2020-06 did not have a material impact on the consolidated financial statements.

XML

Assets Held for Sale and Discontinued Operations (Tables)

9 Months Ended

Sep. 30, 2022

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations

The following assets and liabilities allocated to the discontinued operation are reflected as assets and liabilities of discontinued operations in the Company’s Consolidated Balance Sheet for the period presented. The major classes of assets and liabilities included as part of discontinued operations as of December 31, 2021, are presented in the following table:

(USD in thousands, except share and per share amounts)	December 31, 2021
Assets held for sale
Cash and cash equivalents	$	14
Trade receivables (net of allowances for credit losses of $19 and $40, respectively)	447
Deferred commissions	500
Prepaid expenses and other receivables	121
Long-term deferred commissions	412
Long-term lease deposits and prepaid expenses	123
Operating lease right-of-use assets	3,073
Property and equipment, net	203
Intangible assets, net	805
Goodwill	8,776
Total assets held for sale	$	14,474
Liabilities held for sale
Trade payables	$	16
Employees and payroll accruals	218
Accrued expenses and other liabilities	18
Operating lease liabilities	288
Deferred revenues - current	1,640
Deferred revenues - long-term	413
Long-term operating lease liabilities	2,875
Deferred tax liability, net	240
Total liabilities held for sale	$	5,708

The following details the Company's results of discontinued operations.

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands, except share and per share amounts)	2022		2021		2022		2021
Revenues	$	441	$	1,845	$	3,397	$	5,661
Cost of revenues	88		421		870		1,391
Gross profit	353		1,424		2,527		4,270
Operating expenses:
Research and development, net	139		584		1,140		1,854
Sales and marketing	19		338		484		1,057
General and administrative	36		174		371		539
Total operating expenses	194		1,096		1,995		3,450
Operating gain	159		328		532		820
Other income (expense), net	(34)		1		(33)		1
Financial expenses, net	(505)		(38)		(517)		(116)
Income (loss) from discontinued operations before taxes on income	(380)		291		(18)		705
Loss on sale	(195)		—		(6,985)		—
Total income (loss) from discontinued operations before taxes on income	(575)		291		(7,003)		705
Tax benefit	—		40		74		138
Net income (loss) from discontinued operations	(575)		331		(6,929)		843

The following table presents the loss associated with the sale, presented in the results of discontinued operations:

Gross purchase price	$	10,264
Transaction costs	(1,422)
Provision	(439)
Net assets sold	(12,286)
Realized foreign currency translation adjustments	(3,102)
Total net loss on divestiture	$	(6,985)

XML

Leases (Tables)

9 Months Ended

Sep. 30, 2022

Leases [Abstract]

Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities

Below is a summary of the Company’s operating ROU assets and operating lease liabilities as of September 30, 2022:

	(Unaudited and USD in thousands)
Operating lease right-of-use assets	$	5,265
Operating lease liabilities, current	1,083
Operating lease liabilities long-term	4,293
Total operating lease liabilities	$	5,376

Schedule of Minimum Lease Payments

Minimum lease payments for the Company’s ROU assets over the remaining lease periods as of September 30, 2022, adjusted for discontinued operations, are as follows:

Year ended September 30,	(Unaudited and USD in thousands)
2022	$	314
2023	1,280
2024	1,127
2025	1,058
2026	1,001
Thereafter	1,141
Total undiscounted lease payments	$	5,921
Less: Interest	545
Present value of lease liabilities	$	5,376

Schedule of Weighted Average Remaining Lease Terms and Discount Rates For All of Operating Leases

The weighted-average remaining lease terms and discount rates for all operating leases were as follows as of September 30, 2022:

Weighted-average remaining lease term (years)	5.1
Weighted-average discount rate	4.10	%

XML

Shareholders’ Equity (Tables)

9 Months Ended

Sep. 30, 2022

Stockholders' Equity Note [Abstract]

Schedule of Employees and Directors' Stock Option Activity

A summary of the Company’s employees and directors’ stock option activity under the plans is as follows:

(Unaudited and USD in thousands, except share prices)	Number of options	Weighted- average exercise price		Weighted- average remaining contractual term (years)	Aggregate intrinsic value
Outstanding at December 31, 2021	181,286	$	38.58	2.74	$	—
Granted	—	—		0	—
Exercised	—	—		0	—
Expired and forfeited	(35,388)	33.61		0	—
Outstanding at September 30, 2022	145,898	$	40.09	2.30	$	—
Options vested at September 30, 2022	143,934	$	40.24	2.29	$	—
Exercisable options at September 30, 2022	121,871	$	41.92	2.08	$	—

Schedule of Employee and Directors’ Options Outstanding

The employee and directors’ options outstanding as of September 30, 2022, is separated into ranges of exercise prices as presented below:

Outstanding					Exercisable
Exercise price per share	Options outstanding	Weighted- average remaining contractual life in years	Weighted- average exercise price per share		Options exercisable	Weighted- average exercise price per share
$6.40 - $32.80	30,841	3.50	$	26.23	19,034	$	29.58
$34.00 - $40.00	24,001	1.20	$	38.54	21,294	$	39.07
$41.80 - $42.00	54,300	2.59	$	41.80	45,300	$	41.80
$46.00 - $64.00	36,756	1.60	$	50.23	36,243	$	50.22
Total employee and director options outstanding	145,898	2.30	$	40.09	121,871	$	41.92

Schedule of Options to Non-Employees and Non-Directors

Options to non-employees and non-directors are disclosed as follows:

Issuance date	Options outstanding	Exercise price per share		Options exercisable	Exercisable through
January 24, 2017	1,250	$	40.00	1,250	Jan-23

Schedule of RSUs Activity for Employees, Directors and Non-Employees

A summary of the Company’s RSUs activity for employees, directors and non-employees under the plans is as follows:

	Number of RSUs	Weighted- Average Grant Date Fair Value
Awarded and unvested at December 31, 2021	344,307	$	18.20
Granted	713,050	1.74
Vested	(100,634)	20.57
Forfeited	(78,246)	17.18
Awarded and unvested at September 30, 2022	878,477	$	4.66

Schedule of Stock-Based Compensation Expense

The total share-based compensation expense related to all of the Company’s equity-based awards, recognized for the three and nine-month periods ended September 30, 2022, and 2021 was as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands)	2022		2021		2022		2021
Cost of revenues	$	43	$	76	$	152	$	166
Research and development	45		46		148		125
Sales and marketing	97		100		283		225
General and administrative	346		512		1,053		1,189
Total share-based compensation expense from continuing operations	$	531	$	734	$	1,636	$	1,705
Share-based compensation expense included in discontinued operations	(2)		18		11		52
Total share-based compensation expense	$	529	$	752	$	1,647	$	1,757

XML

Basic and Diluted Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands, except share amounts)	2022		2021		2022		2021
Numerator - continuing operations
(Loss) from continuing operations	$	(5,523)	$	(6,118)	$	(18,088)	$	(16,415)
Numerator - discontinued operations
Net income (loss) from discontinued operations	$	(575)	$	331	$	(6,929)	$	843
Denominator
Denominator for basic net loss per share weighted-average number of shares outstanding	7,822,424		3,899,502		6,858,937		3,700,789
Effect of diluting securities*	—		772,330		—		757,157
Denominator for diluted net loss per share - adjusted weighted average shares and assumed exercises	7,822,424		4,671,832		6,858,937		4,457,946
* For the discontinued operations, the total number of ordinary shares related to share-based compensation plans, aggregated to 613,377 and 683,156, for the three and nine months ended September 30, 2022, respectively, was excluded from the calculations of diluted loss per ordinary share since it would have an anti-dilutive effect.

XML

Segment and Geographic Information (Tables)

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Schedule of Total Revenue by Solutions Offered by Geographic Area

The following presents total revenue by solutions offered by geographic area based on the billing address of the customer from continuing operations:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands)	2022		2021		2022		2021
United States	$	3,375	$	3,103	$	9,739	$	10,104
Germany	447		381		1,294		1,198
Europe-Other	768		756		2,509		2,412
Asia Pacific	581		401		1,432		1,480
Israel	544		849		1,967		2,610
Other	119		126		361		362
Total revenue	$	5,834	$	5,616	$	17,302	$	18,166

Schedule of Revenue Generated By Customer Type

The following presents the Company's revenue by customer type from continuing operations:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands)	2022		2021		2022		2021
OEM/Embedded Security1	$	5,515	$	5,423	$	16,389	$	17,625
Enterprise/SMB2	287		193		881		541
Other	32		—		32		—
Total Revenue	$	5,834	$	5,616	$	17,302	$	18,166
1 This market represents customers who embed Cyren Threat Detection Services and Threat Intelligence Service feeds into their infrastructure and/or products to protect their customers and users.
2 In this market, Cyren provides enterprise as well as small and midsize business customers email security products and threat intelligence to help protect their employees, data and IP.

Schedule of Long-Lived Tangible Assets

The following sets forth the Company’s long-lived tangible assets, net by geographic area from continuing operations:

(Unaudited and USD in thousands)	September 30, 2022		December 31, 2021
Israel	$	4,921	$	5,612
United States	541		1,017
Germany	219		669
Other	710		889
Total long-lived tangible assets	$	6,391	$	8,187

XML

Financial Expenses, Net (Tables)

9 Months Ended

Sep. 30, 2022

Financial Services Costs [Abstract]

Schedule of financial expense, net

The following sets forth the Company’s financial income (expense), net by expense type from continuing operations:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands)	2022		2021		2022		2021
Interest and accretion of discount	$	(213)	$	(331)	$	(640)	$	(960)
Foreign currency exchange differences, net	219		47		800		254
Other	(13)		2		(56)		1
Total financial expenses, net	$	(7)	$	(282)	$	104	$	(705)

XML

Related Parties (Tables)

9 Months Ended

Sep. 30, 2022

Related Party Transactions [Abstract]

Schedule of Related Party Balances

The following sets forth balances with related parties:

(Unaudited and USD in thousands)	September 30, 2022		December 31, 2021
Interest expense accrual – Convertible Debentures1	$	—	$	4
Long-term Convertible Debentures2	242		238
1 Related to the semi-annual interest payable due in March and September related to the Convertible Debentures entered into March 19, 2020. See Note 6 - Shareholders' Equity for further details.
2 Related to the Convertible Debentures entered into March 19, 2020. See Note 6 - Shareholders' Equity for further details.

Schedule of Related Party Transactions

The following sets forth transactions with related parties:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Unaudited and USD in thousands)	2022		2021		2022		2021
Revenue1	$	25	$	—	$	75	$	—
Interest expense on Convertible Notes2	$	—	$	143	$	—	$	285
Interest expense on Convertible Debentures3	$	5	$	5	$	15	$	10
1 Related to a new OEM customer agreement signed in Q3 2021 where the Company and this customer share an investor that qualifies as a related party for each.
2 Related to the semi-annual interest payable due in June and December related to the Convertible Note entered into December 5, 2018. The principal was repaid in December 2021. See Note 6 - Shareholders' Equity for further details.
3 Related to the semi-annual interest payable due in March and September related to the Convertible Debentures entered into March 19, 2020. See Note 6 - Shareholders' Equity for further details.

XML

Organization (Details) $ / shares in Units, $ in Thousands, € in Millions				9 Months Ended
	Aug. 01, 2022 USD ($)	Aug. 01, 2022 EUR (€)	Feb. 10, 2022 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) segment	Sep. 30, 2021 USD ($)	Aug. 01, 2022 EUR (€)	Jun. 01, 2022 EUR (€)	Dec. 31, 2021 USD ($)	Sep. 17, 2021 $ / shares	Feb. 16, 2021 $ / shares
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of reportable segments | segment				1
Accumulated deficit | $				$ (296,648)				$ (271,631)
Negative cash flows, operating activities | $				(8,972)	$ (12,462)
Purchase price, per share (in dollars per share)									$ 0.72	$ 1.15
Exercise price, per share (in dollars per share)									$ 0.60
Transaction costs | $	$ 1,400			1,422
Purchase price reduction | $				$ 400
Pre-Funded warrants
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Exercise price, per share (in dollars per share)			$ 0.001
Ordinary Warrants
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Exercise price, per share (in dollars per share)			$ 3.71
Private placement
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of ordinary shares (in shares) | shares			760,757
Consideration received on transaction | $			$ 12,000
Purchase price, per share (in dollars per share)			$ 3.835
Purchase price of warrants per share (in dollars per share)			$ 3.834
Private placement | Pre-Funded warrants
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of securities called by warrants or rights (in shares) | shares			2,368,318
Private placement | Ordinary Warrants
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of securities called by warrants or rights (in shares) | shares			3,129,075
Legacy secure email gateway business and Cyren GmbH
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Payment	$ 9,600					€ 9.4	€ 10.0
Holdback amount | €		€ 0.7

XML

Assets Held for Sale and Discontinued Operations - Narrative (Details) $ in Millions	Sep. 30, 2022 USD ($)
Discontinued Operations and Disposal Groups [Abstract]
Purchase price reduction	$ 0.4

XML

Assets Held for Sale and Discontinued Operations - Balance Sheets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Assets held for sale
Allowance for credit losses	$ 19	$ 40
Liabilities held for sale
Deferred revenues - long-term		413
Legacy secure email gateway business and Cyren GmbH
Assets held for sale
Cash and cash equivalents		14
Trade receivables (net of allowances for credit losses of $19 and $40, respectively)		447
Deferred commissions		500
Prepaid expenses and other receivables		121
Long-term deferred commissions		412
Long-term lease deposits and prepaid expenses		123
Operating lease right-of-use assets		3,073
Property and equipment, net		203
Intangible assets, net		805
Goodwill		8,776
Total assets held for sale		14,474
Liabilities held for sale
Trade payables		16
Employees and payroll accruals		218
Accrued expenses and other liabilities		18
Operating lease liabilities		288
Deferred revenues - current		1,640
Long-term operating lease liabilities		2,875
Deferred tax liability, net		240
Total liabilities held for sale		$ 5,708

XML

Assets Held for Sale and Discontinued Operations - Results of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross profit	$ 353	$ 1,424	$ 2,527	$ 4,270
Total operating expenses	194	1,096	1,995	3,450
Operating gain	159	328	532	820
Income (loss) from discontinued operations before taxes on income	(380)	291	(18)	705
Loss on sale	(195)	0	(6,985)	0
Total income (loss) from discontinued operations before taxes on income	(575)	291	(7,003)	705
Net income (loss) from discontinued operations	(575)	331	(6,929)	843
Legacy secure email gateway business and Cyren GmbH
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues	441	1,845	3,397	5,661
Cost of revenues	88	421	870	1,391
Research and development, net	139	584	1,140	1,854
Sales and marketing	19	338	484	1,057
General and administrative	36	174	371	539
Other income (expense), net	(34)	1	(33)	1
Financial expenses, net	(505)	(38)	(517)	(116)
Tax benefit	$ 0	$ 40	$ 74	$ 138

XML

Discontinued Operations and Disposal Groups - Discontinued Operations (Details) - USD ($) $ in Thousands		9 Months Ended
	Aug. 01, 2022	Sep. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
Gross purchase price		$ 10,264
Transaction costs	$ (1,400)	(1,422)
Provision		(439)
Net assets sold		12,286
Realized foreign currency translation adjustments		(3,102)
Gain (Loss) on Disposition of Business		$ (6,985)

XML

Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Rent expense	$ 430	$ 574	$ 1,469	$ 1,780
Sublease receipts	$ 10	$ 167	$ 202	$ 496

XML

Leases (Details) - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Operating lease right-of-use assets	$ 5,265	$ 6,207
Operating lease liabilities, current	1,083	1,330
Operating lease liabilities long-term	4,293	$ 5,749
Total operating lease liabilities	$ 5,376

XML

Leases (Details) - Schedule of Minimum Lease Payments $ in Thousands	Sep. 30, 2022 USD ($)
Leases [Abstract]
2022	$ 314
2023	1,280
2024	1,127
2025	1,058
2026	1,001
Thereafter	1,141
Total undiscounted lease payments	5,921
Less: Interest	545
Operating lease liabilities	$ 5,376

XML

Leases (Details) - Schedule of Weighted Average Remaining Lease Terms and Discount Rates For All of Operating Leases	Sep. 30, 2022
Leases [Abstract]
Weighted-average remaining lease term (years)	5 years 1 month 6 days
Weighted-average discount rate	4.10%

XML

Commitments and Contingencies (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Research and development	$ 6,400		$ 6,400
Subject to repayment (in Shares)	2,600		2,600
Cost of revenues	$ 0	$ 31	$ 0	$ 90
Royalty payments based on developed product sales	3.00%		3.00%
Royalty payments based on grants received	100.00%		100.00%

XML

Shareholders’ Equity (Details) ₪ / shares in Units, $ / shares in Units, ₪ in Millions								1 Months Ended					3 Months Ended			9 Months Ended		12 Months Ended
	Feb. 09, 2022 ILS (₪) ₪ / shares shares	Feb. 07, 2022 ILS (₪)	Dec. 05, 2021 USD ($)	Feb. 16, 2021 USD ($) $ / shares shares	Nov. 07, 2019 USD ($) $ / shares	Dec. 05, 2018 USD ($) $ / shares	Dec. 22, 2016	Sep. 30, 2022 USD ($) $ / shares shares	Mar. 31, 2022 USD ($) shares	Sep. 30, 2021 USD ($) shares	Mar. 31, 2021 USD ($) shares	Mar. 31, 2020 USD ($)	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($) $ / shares	Jun. 30, 2021 USD ($) shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Aug. 31, 2022 shares	Feb. 10, 2022 $ / shares	Sep. 17, 2021 $ / shares shares	Jul. 30, 2019 shares
Shareholders’ Equity (Details) [Line Items]
Share capital (in new shekels) | ₪	₪ 240.0
Reverse stock split ratio		0.05
Ordinary share, par value (in new shekels per share) | ₪ / shares	₪ 3.00
Principal amount of convertible debenture						$ 10,000,000
Interest rate						5.75%
Interest payable in cash only						50.00%
Interest payable in cash or stock						50.00%
Matured term						3 years
Conversion price, per share (in dollars per share) | $ / shares				$ 3.38	$ 3.73	$ 3.90															$ 3.02
Gross proceeds					$ 8,000,000
Direct offering (in shares) | shares				12,000,000
Purchase price, per share (in dollars per share) | $ / shares				$ 1.15																	$ 0.72
Net proceeds				$ 12,600,000
Shares issued (in shares) | shares																					14,152,779
Share warrants (in shares) | shares																					14,152,779
Exercise price, per share (in dollars per share) | $ / shares																					$ 0.60
Interest expense													$ 0	$ 100,000		$ 0	$ 400,000
Net issuance expenses												$ 800,000
Interest payments								$ 300,000	$ 300,000	$ 300,000	$ 300,000
Issuance of shares (in shares) | shares								190,272	31,667	16,726	14,572
Converted of principal															$ 1,000,000
Principal and interest issuance of shares (in shares) | shares															60,074
Incurred interest expense													176,000	180,000		520,000	523,000
Amortization of debt issuance costs													48,000	44,000		139,000	134,000
Accrued interest																0		$ 137,000
Principal balance of convertible debentures													$ 8,700,000
Fair market value percentage													100.00%
Intrinsic value								$ 0		$ 0			$ 0	$ 0		0	$ 0
Number of options, granted (in shares) | shares													0
Weighted average grant date value of option granted (in dollars per share) | $ / shares														$ 0.39
Unrecognized compensation expense								$ 300,000					$ 300,000			$ 300,000
Recognized over remaining weighted average period																1 year 1 month 9 days
Equity incentive plan
Shareholders’ Equity (Details) [Line Items]
Ordinary shares reserved for issuance (in shares) | shares								440,309					440,309			440,309
Non-employee plan
Shareholders’ Equity (Details) [Line Items]
Ordinary shares available for future grant (in shares) | shares								55,367					55,367			55,367
Minimum
Shareholders’ Equity (Details) [Line Items]
Share capital (in new shekels) | ₪		₪ 216.0
Maximum
Shareholders’ Equity (Details) [Line Items]
Share capital (in new shekels) | ₪		240.0
Israeli appendix | Non-employee plan
Shareholders’ Equity (Details) [Line Items]
Number of ordinary shares reserved for issuance (in shares) | shares																			182,500			57,500
Private placement
Shareholders’ Equity (Details) [Line Items]
Reverse share split (in shares) | shares	80,000,000
Purchase price, per share (in dollars per share) | $ / shares																				$ 3.835
Restricted Stock Units (RSUs)
Shareholders’ Equity (Details) [Line Items]
Vesting period																4 years
Expiration term																6 years
Number of options, granted (in shares) | shares																713,050
Unrecognized compensation expense								$ 3,400,000					$ 3,400,000			$ 3,400,000
Recognized over remaining weighted average period																2 years 1 month 20 days
Options
Shareholders’ Equity (Details) [Line Items]
Vesting period																4 years
Expiration term							6 years
2016 Equity Incentive Plan | Israeli appendix
Shareholders’ Equity (Details) [Line Items]
Ordinary shares reserved for issuance (in shares) | shares																			1,225,000			560,000
Board of directors
Shareholders’ Equity (Details) [Line Items]
Share capital (in new shekels) | ₪		₪ 216.0
Issuance of convertible notes
Shareholders’ Equity (Details) [Line Items]
Convertible notes			$ 10,000,000
Convertible notes payable
Shareholders’ Equity (Details) [Line Items]
Principal amount of convertible debenture								$ 1,000,000				10,300,000	$ 1,000,000			$ 1,000,000
Interest rate													5.75%
Convertible debentures
Shareholders’ Equity (Details) [Line Items]
Principal amount of convertible debenture												$ 9,400,000
Conversion price, per share (in dollars per share) | $ / shares								$ 15.00					$ 15.00			$ 15.00
Convertible shares (in shares) | shares													67

XML

Shareholders’ Equity (Details) - Schedule of Employees and Directors' Stock Option Activity - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021
Number of options
Number of options, granted (in shares)	0
Number of options, outstanding ending balance (in shares)	145,898		145,898
Number of options, exercisable options (in shares)	121,871		121,871
Weighted- average exercise price
Weighted average exercise price, outstanding ending balance (in USD per share)	$ 40.09		$ 40.09
Weighted average exercise price, exercisable options (in USD per share)	$ 41.92		$ 41.92
Additional Disclosures:
Weighted average remaining contractual term (years), outstanding beginning balance			2 years 3 months 18 days
Aggregate intrinsic value, exercisable options	$ 0		$ 0		$ 0
Employees and directors' stock option
Number of options
Number of options, outstanding beginning balance (in shares)		181,286	181,286
Number of options, granted (in shares)	0
Number of options, exercised (in shares)	0
Number of options, expired and forfeited (in shares)	(35,388)
Number of options, outstanding ending balance (in shares)	145,898		145,898
Number of options, options vested and expected to vest (in shares)	143,934		143,934
Number of options, exercisable options (in shares)	121,871		121,871
Weighted- average exercise price
Weighted average exercise price, outstanding beginning balance (in USD per share)		$ 38.58	$ 38.58
Weighted average exercise price, granted (in USD per share)	$ 0
Weighted average exercise price, exercised (in USD per share)	0
Weighted average exercise price, expired and forfeited (in USD per share)	33.61
Weighted average exercise price, outstanding ending balance (in USD per share)	40.09		40.09
Weighted average exercise price, options vested and expected to vest (in USD per share)	40.24		40.24
Weighted average exercise price, exercisable options (in USD per share)	$ 41.92		$ 41.92
Additional Disclosures:
Weighted average remaining contractual term (years), outstanding beginning balance		2 years 8 months 26 days
Weighted average remaining contractual term (years), outstanding ending balance			2 years 3 months 18 days
Aggregate intrinsic value, outstanding	$ 0		$ 0	$ 0
Weighted average remaining contractual term (years), options vested and expected to vest			2 years 3 months 14 days
Aggregate intrinsic value, options vested and expected to vest	0		$ 0
Weighted average remaining contractual term (years), exercisable options			2 years 29 days
Aggregate intrinsic value, exercisable options	$ 0		$ 0

XML

Shareholders’ Equity (Details) - Schedule of Employee and Directors’ Options Outstanding	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding (in shares) | shares	145,898
Weighted- average remaining contractual life in years	2 years 3 months 18 days
Outstanding, weighted- average exercise price per share (in dollars per share)	$ 40.09
Exercisable, options exercisable (in shares) | shares	121,871
Exercisable, weighted- average exercise price per share (in dollars per share)	$ 41.92
$6.40 - $32.80
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price per share lower limit (in dollars per share)	6.40
Exercise price per share upper limit (in dollars per share)	$ 32.80
Options outstanding (in shares) | shares	30,841
Weighted- average remaining contractual life in years	3 years 6 months
Outstanding, weighted- average exercise price per share (in dollars per share)	$ 26.23
Exercisable, options exercisable (in shares) | shares	19,034
Exercisable, weighted- average exercise price per share (in dollars per share)	$ 29.58
$34.00 - $40.00
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price per share lower limit (in dollars per share)	34.00
Exercise price per share upper limit (in dollars per share)	$ 40.00
Options outstanding (in shares) | shares	24,001
Weighted- average remaining contractual life in years	1 year 2 months 12 days
Outstanding, weighted- average exercise price per share (in dollars per share)	$ 38.54
Exercisable, options exercisable (in shares) | shares	21,294
Exercisable, weighted- average exercise price per share (in dollars per share)	$ 39.07
$41.80 - $42.00
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price per share lower limit (in dollars per share)	41.80
Exercise price per share upper limit (in dollars per share)	$ 42.00
Options outstanding (in shares) | shares	54,300
Weighted- average remaining contractual life in years	2 years 7 months 2 days
Outstanding, weighted- average exercise price per share (in dollars per share)	$ 41.80
Exercisable, options exercisable (in shares) | shares	45,300
Exercisable, weighted- average exercise price per share (in dollars per share)	$ 41.80
$46.00 - $64.00
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price per share lower limit (in dollars per share)	46.00
Exercise price per share upper limit (in dollars per share)	$ 64.00
Options outstanding (in shares) | shares	36,756
Weighted- average remaining contractual life in years	1 year 7 months 6 days
Outstanding, weighted- average exercise price per share (in dollars per share)	$ 50.23
Exercisable, options exercisable (in shares) | shares	36,243
Exercisable, weighted- average exercise price per share (in dollars per share)	$ 50.22

XML

Shareholders’ Equity (Details) - Schedule of Options to Non-Employees and Non-Directors	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Shareholders’ Equity (Details) - Schedule of options to non-employees and non-directors [Line Items]
Options outstanding (in shares)	145,898
Exercise price per share (in dollars per share) | $ / shares	$ 40.09
Options exercisable (in shares)	121,871
January 24, 2017
Shareholders’ Equity (Details) - Schedule of options to non-employees and non-directors [Line Items]
Options outstanding (in shares)	1,250
Exercise price per share (in dollars per share) | $ / shares	$ 40.00
Options exercisable (in shares)	1,250
Exercisable through	Jan-23

XML

Shareholders’ Equity (Details) - Schedule of RSUs Activity for Employees, Directors and Non-Employees - $ / shares	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Number of RSUs
Number of RSUs, granted (in shares)	0
Restricted Stock Units (RSUs)
Number of RSUs
Number of RSUs awarded and unvested, beginning balance (in shares)		344,307
Number of RSUs, granted (in shares)		713,050
Number of RSUs, vested (in shares)		(100,634)
Number of RSUs, forfeited (in shares)		(78,246)
Number of RSUs awarded and unvested, ending balance (in shares)	878,477	878,477
Weighted- Average Grant Date Fair Value
Weighted average grant date fair value awarded and unvested, beginning balance (in USD per share)		$ 18.20
Weighted average grant date fair value, granted (in USD per share)		1.74
Weighted average grant date fair value, vested (in USD per share)		20.57
Weighted average grant date fair value, forfeited (in USD per share)		17.18
Weighted average grant date fair value awarded and unvested, ending balance (in USD per share)	$ 4.66	$ 4.66

XML

Shareholders’ Equity (Details) - Schedule of Stock-Based Compensation Expense - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	$ 529	$ 752	$ 1,647	$ 1,757
Continuing Operations
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	531	734	1,636	1,705
Discontinued Operations
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	(2)	18	11	52
Cost of revenues
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	43	76	152	166
Research and development
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	45	46	148	125
Sales and marketing
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	97	100	283	225
General and administrative
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation expense	$ 346	$ 512	$ 1,053	$ 1,189

XML

Basic and Diluted Net Loss Per Share (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Net loss from continuing operations	$ (5,523)	$ (6,118)	$ (18,088)	$ (16,415)
Net income (loss) from discontinued operations	$ (575)	$ 331	$ (6,929)	$ 843
Weighted-average number of shares used in computing basic net loss per share for continuing operations (in shares)	7,822,424	3,899,502	6,858,937	3,700,789
Effect of diluting securities (in shares)	0	772,330	0	757,157
Weighted-average numbers of shares used in computing diluted net loss per share in discontinued operations (in shares)	7,822,424	4,671,832	6,858,937	4,457,946
Share-based compensation, aggregate shares issued, discontinued operations (in shares)	613,377		683,156

XML

Segment and Geographic Information - Additional Information (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) segment	Sep. 30, 2021 USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment			1
Recognized from deferred revenue	$ 3.1	$ 3.4	$ 6.2	$ 8.9
Revenue remaining performance obligations	$ 9.2		$ 9.2
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01
Concentration Risk [Line Items]
Revenue remaining performance obligation	26.00%		26.00%
Revenue remaining performance obligation, term	3 months		3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Concentration Risk [Line Items]
Revenue remaining performance obligation	51.00%		51.00%
Revenue remaining performance obligation, term	1 year		1 year
Revenue Benchmark | Customer Concentration Risk | Largest Customer
Concentration Risk [Line Items]
Concentration risk	23.00%	22.00%

XML

Segment and Geographic Information (Details) - Schedule of Total Revenue by Solutions Offered by Geographic Area - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	$ 5,834	$ 5,616	$ 17,302	$ 18,166
United States
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	3,375	3,103	9,739	10,104
Germany
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	447	381	1,294	1,198
Europe-Other
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	768	756	2,509	2,412
Asia Pacific
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	581	401	1,432	1,480
Israel
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	544	849	1,967	2,610
Other
Segment and Geographic Information (Details) - Schedule of total revenue by solutions offered by geographic area [Line Items]
Revenues from external customers	$ 119	$ 126	$ 361	$ 362

XML

Segment and Geographic Information (Details) - Schedule of Revenue Generated By Customer Type - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue from External Customer [Line Items]
Revenues from external customers	$ 5,834	$ 5,616	$ 17,302	$ 18,166
OEM/Embedded Security
Revenue from External Customer [Line Items]
Revenues from external customers	5,515	5,423	16,389	17,625
Enterprise/SMB
Revenue from External Customer [Line Items]
Revenues from external customers	287	193	881	541
Other
Revenue from External Customer [Line Items]
Revenues from external customers	$ 32	$ 0	$ 32	$ 0

XML

Segment and Geographic Information (Details) - Schedule of Long-Lived Tangible Assets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Segment and Geographic Information (Details) - Schedule of long-lived tangible assets [Line Items]
Net amount of property and equipment	$ 6,391	$ 8,187
Israel
Segment and Geographic Information (Details) - Schedule of long-lived tangible assets [Line Items]
Net amount of property and equipment	4,921	5,612
United States
Segment and Geographic Information (Details) - Schedule of long-lived tangible assets [Line Items]
Net amount of property and equipment	541	1,017
Germany
Segment and Geographic Information (Details) - Schedule of long-lived tangible assets [Line Items]
Net amount of property and equipment	219	669
Other
Segment and Geographic Information (Details) - Schedule of long-lived tangible assets [Line Items]
Net amount of property and equipment	$ 710	$ 889

XML

Financial Expenses, Net (Details) - Schedule of financial expense, net - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Expenses:
Interest and accretion of discount	$ (213)	$ (331)	$ (640)	$ (960)
Foreign currency exchange differences, net	219	47	800	254
Other	(13)	2	(56)	1
Total financial expenses, net	$ (7)	$ (282)	$ 104	$ (705)

XML

Related Parties (Details) - Schedule of Related Party Balances - USD ($)	3 Months Ended
	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Related Party Transactions [Abstract]
Interest expense accrual – convertible debentures	$ 0	$ 4,000
Long term convertible debentures	$ 242,000		$ 238,000

XML

Related Parties (Details) - Schedule of Transactions With Related Parties - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Related Party Transactions [Abstract]
Revenue	$ 25	$ 0	$ 75	$ 0
Interest expense on Convertible Notes	0	143	0	285
Interest expense on Convertible Debentures	$ 5	$ 5	$ 15	$ 10